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Abstract 
Objective: The effect of chronic, systemic inflammation on muscle tissue is largely unknown. 
The purpose of this study was to investigate body composition, muscle function and muscle 
morphology in patients with spondyloarthritis (SpA).  
Methods: Ten male SpA patients (mean ±SD age 39 ±4.1 years) were compared with ten 
healthy controls matched for age, body mass index and self-reported level of exercise. Body 
composition was measured by dual energy X-ray absorptiometry. Quadriceps femoris (QF) 
strength was assessed by maximal isometric contractions prior to test of muscular endurance. 
Magnetic resonance imaging of QF was used to calculate specific muscle strength. 
Percutaneous needle biopsy samples were taken from m. vastus lateralis.  
Results: SpA patients presented with significantly lower appendicular lean body mass (LBM) 
(p= 0.02), but there was no difference in bone mineral density, fat mass or total LBM. 
Absolute and specific strength of the left QF was significantly lower in SpA patients (p= 0.01 
and 0.04) with a parallel trend observed for the right leg. Biopsy samples from the SpA 
patients revealed significantly smaller cross-sectional area (CSA) of type 2 muscle fibers (p= 
0.04), but no difference in CSA type 1 fibers.   
Conclusion: Results indicate that the presence of SpA disease is associated with reduced 
appendicular LBM, muscle strength and type 2 fiber CSA. Further research is needed to 
investigate whether catabolic pathways are up-regulated in SpA patients. Strength training 
may be an effective countermeasure against these negative effects on muscle indicated in SpA 
patients. 
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1. Introduction 
The previous decades have provided insight regarding the important role of physical activity 
and physical fitness in prevention and treatment of a wide range of diseases (Wen et al., 
2011). Global recommendations issued by the World Health Organization promote habitual 
physical activity for all age groups, stating that the health benefits outweigh potential harms 
(WHO, 2014). Recent studies have linked sedentary time to increased risk of various diseases 
and shown an inverse correlation between physical activity and lifestyle disease (Grontved & 
Hu, 2011; Sattelmair et al., 2011). The benefits of exercise may reduce the burden of disease 
and curtail the use of health services and possibly also the need for pharmacological 
treatment. For some patient groups, regular physical activity can possibly lead to a more 
benign disease course and reduce social costs.  
The Norwegian Directorate of Health recommend that all adults engage in resistance exercise 
at least twice a week (Helsedirektoratet, 2014). For healthy individuals, physiological 
adaptations to various subtypes of resistance training are well established and the benefits of 
regular resistance training are many (ACSM, 2009; Wernbom, Augustsson, & Thomee, 
2007). It is however unclear whether we can directly translate the resistance exercise 
recommendations for healthy adults to include patients with a chronic, inflammatory disease. 
The effect of chronic, systemic inflammatory disease on skeletal muscle tissue is largely 
unknown. Consequently, exploring whether there are pathological changes in muscle tissue in 
patients with spondyloarthritis (SpA) can provide useful insight. Furthermore, such 
knowledge may have implications in how we prescribe resistance training for this patient 
group. 
1.1 Aim 
The aim of this study was to compare body composition, muscle function and muscle 
morphology in SpA patients to healthy controls. Results of the study may provide insight into 
whether there are differences between SpA patients and controls concerning the items listed 
above. The results may generate future hypotheses concerning whether we can assume that 
patients with SpA will adapt to strength training in the same manner as the general 
population, or if we may need to modify resistance exercise recommendations to better suit 
patients with SpA. 
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1.2  Master thesis 
Do male patients with SpA differ in body composition, muscle function or muscle morphology 
compared to healthy controls? 
Null hypothesis: None of body composition, quadriceps femoris (QF) muscle function and QF 
muscle morphology differ between male patients aged 30-45 with SpA and healthy controls.  
Alternative hypothesis: One or more of body composition, QF muscle function or QF muscle 
morphology differ between male patients aged 30-45 with SpA and healthy controls. 
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2. Theory 
2.1 Spondyloarthritis 
SpA is a chronic, inflammatory rheumatic disease. The prevalence estimates to 0.3-0.7 %, 
with disease onset frequently reported at a young adult age (Haglund et al., 2011; Strand et 
al., 2013). SpA has been reported to be predominant in males, although some studies show 
that prevalence among women is higher than what has traditionally been accepted (Lee, 
Reveille, & Weisman, 2008).  The term SpA designates several diseases that share certain 
clinical and genetic features. Ankylosing Spondylitis (AS) is often viewed as the prototype of 
SpA as well as the most severe subtype (Ozgocmen & Khan, 2012; Raychaudhuri & Deodhar, 
2014) (Ozgocmen & Khan, 2012). This paper will further consider SpA as one disease, but 
signify different subtypes when appropriate. 
SpA symptoms generally precede clinical diagnosis, with an average diagnostic delay of 
about six years in AS. Typical disease characteristics include inflammatory axial pain, 
asymmetrical and peripheral oligoarthritis, and enthesopathy. Extra-articular manifestations 
such as anterior uveitis, psoriasis, and chronic inﬂammatory bowel disease are also common 
(Braun & Sieper, 2007; Khan, 2011). Inflammation in SpA may lead to bony erosion and joint 
destruction, similar to the pathophysiology seen in rheumatoid arthritis (RA). However, in 
contrast to other rheumatic diseases, axial SpA is also accompanied by axial bone formation 
in the form of syndesmophytes1 (Lories & Baeten, 2009).  
2.1.1 SpA and physical function 
Characteristic clinical features of SpA are axial pain and stiffness, possibly leading to 
functional impairment (Dougados & Baeten, 2011). Functional loss can be reversible in 
response to various therapeutic modalities or change in disease activity. However, SpA may 
also entail irreversible structural changes such as reduced spinal mobility and chest expansion 
(Landewe, Dougados, Mielants, van der Tempel, & van der Heijde, 2009). This is often a 
consequence of long-standing disease and is for instance associated with reduced pulmonary 
function (Berdal, Halvorsen, van der Heijde, Mowe, & Dagfinrud, 2012). However, patient-
reported function is reported to be only moderately correlated to radiographic changes 
(Landewe et al., 2009), indicating that SpA patients may function well despite structural 
                                                 
1 Syndesmophytes are bony outgrowths from spinal vertebrae  
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damage. Inflammatory rheumatic disease may also involve serious co-morbidity, and SpA 
patients have an increased incidence, mortality and morbidity for cardiovascular disease 
(CVD) compared to the general population (Bremander, Petersson, Bergman, & Englund, 
2011; Mathieu, Gossec, Dougados, & Soubrier, 2011; Papagoras, Voulgari, & Drosos, 2013). 
Researchers are still attempting to discern the horse’s mouth of SpA and increased risk of 
CVD. Studies have shown alterations of traditional CVD risk factors in patients with SpA, 
with systemic inflammation also recognized as an independent risk factor for CVD (Ridker, 
Wilson, & Grundy, 2004). SpA patients with high disease activity report less physical activity 
compared to patients with low disease activity and healthy controls (Fongen, Halvorsen, & 
Dagfinrud, 2013). In agreement, objective measures of physical activity (PA) reveal lower 
weekly energy expenditure values as well as scarce levels of vigorous PA in SpA patients 
matched to healthy controls (Swinnen et al., 2014). Furthermore, the latter study detected no 
significant correlation between self-reported disease activity and level of PA. Discordantly, 
equal levels of PA in AS patients and healthy controls were noted when monitored by tri-axial 
accelerometer, however the sample size was relatively small (n=25 pr. group) (Plasqui et al., 
2012). Additionally, Haglund et al. (2012) report a tendency for Swedish SpA patients to 
fulfill self-reported levels of PA recommendations to a greater extent than the general 
population, although the results may have been clouded by a responder bias in the SpA 
population. Regarding cardiorespiratory fitness, a Norwegian study on a large SpA cohort 
observed significantly lower peak oxygen uptake (VO2peak) in patients vs. controls (Halvorsen 
et al., 2012) when estimated by an indirect maximal test. Although non-significant, Plasqui et 
al. (2012) indicate a similar trend (p= 0.09) towards lower physical fitness in AS patients 
when evaluated by direct measurement of maximal oxygen uptake (VO2max).  
In addition to functional disability, SpA patients report impaired health-related quality of life 
due to domains such as fatigue (Aissaoui et al., 2012), pain (Ozdemir, 2011), activities of 
daily living (Dagfinrud, Kjeken, Mowinckel, Hagen, & Kvien, 2005) and social participation 
(Dagfinrud et al., 2005; van Echteld et al., 2006).  
2.1.2 Inflammatory pathways in SpA 
The etiology and pathogenesis of SpA is unclear although several studies support the notion 
of a genetic susceptibility. Numerous studies have shown a strong association between the 
Human Leukocyte Antigen (HLA) B27 and SpA (Ehrenfeld, 2012; McHugh & Bowness, 
2012). However, only a small proportion of the 6% of the general population that harbor the 
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HLA-B27 gene (Reveille & Weisman, 2013) develop SpA, suggesting that additional genes 
contribute to disease mechanisms in SpA (Ehrenfeld, 2012). Several inflammatory cytokine2 
pathways are implicated in the pathogenesis of SpA. Tumor necrosis factor (TNF) is a cell 
protein that acts as a pivotal inflammatory agent. In animal models, over-expression of TNF 
induces systemic inflammation and synovitis. In vivo inhibition of TNF in SpA patients 
effectively reduces disease symptoms. Anti-TNF therapy is however unsuccessful in blocking 
new bone formation, indicating the presence of additional inflammatory pathways in SpA 
(reviewed in: Hreggvidsdottir, Noordenbos, & Baeten, 2014; Machado et al., 2013). SpA is 
genetically associated with genes coding for interleukin 1 (IL-1), a cytokine that may be 
involved in cartilage and bone destruction. However, IL-1 is also suggested to be upstream to 
interleukin 17 (IL-17) signaling. There is shortage of human in vivo studies linking IL-1 to 
SpA, and the role of IL-1 in disease pathogenesis remains elusive (Hreggvidsdottir et al., 
2014). Interleukin 6 (IL-6) is a pro-inflammatory cytokine that governs acute phase response 
as measured by CRP (see footnote 16). Even though serum levels of IL-6 are raised in AS 
patients, these levels are not necessarily correlated to disease activity. In a review article, 
Hreggvidsdottir et al. (2014) conclude that there is weak evidence from human studies 
assessing the role of IL-6 as a crucial inflammatory cytokine in SpA. There are however 
strong indications for an association between SpA and genes coding for the receptor of 
interleukin 23 (IL-23) (Dougados & Baeten, 2011; Sherlock, Buckley, & Cua, 2014). 
Overexpression of IL-23 in experimental mice models causes enthesitis and enthesal new 
bone formation as well as inflammation at the root and valve of the aorta (Sherlock et al., 
2012). In human SpA, overexpression of IL-23 is found at both a systemic and local level. 
Recognized as a pivotal cytokine, IL-23 also regulates production of pro-inflammatory cell 
signaling molecules interleukin 17 (IL-17) and 22 (IL-22). In SpA, upregulation of IL-17 is 
associated with recruitment of phagocytic white blood cells to the inflammatory scene, while 
IL-22 may lead to increased expression of genes governing bone remodeling (Hreggvidsdottir 
et al., 2014; Sherlock et al., 2014). 
2.1.3 Treatment of SpA 
Optimal medical treatment combined with supervised and tailored exercise is recognized as 
the cornerstone treatment of SpA (Braun et al., 2011). A systematic review of non-
pharmacological treatment of AS concluded that physical therapy exercises in various 
                                                 
2 Cytokine: small proteins that are involved in cellular signaling  
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modalities have positive effects on pain and mobility function (van den Berg, Baraliakos, 
Braun, & van der Heijde, 2012). Patients present with different courses of disease, and 
treatment should be tailored to each individual (Braun et al., 2011; Smolen et al., 2014). 
Pharmacological treatment with non-steroidal anti-inflammatory drugs (NSAIDs) is 
recommended as the first-line drug treatment for axial pain and stiffness (Dougados & 
Baeten, 2011). Some individuals with SpA present with a mild disease course that is 
controlled by on-demand use of NSAIDs, while the majority of patients require continuous 
medication (Braun & Sieper, 2007; Braun et al., 2011). Over the last decade, the introduction 
of biological agents directed against TNF has represented a new therapeutic option for SpA 
patients whom do not respond sufficiently to the use of NSAIDs. TNF blockers target this 
specific protein and may help to reduce stiffness, pain and swollen joints (Machado et al., 
2013). Therapeutic effectiveness of TNF-inhibitors has been enacted in several studies 
(Baraliakos, van den Berg, Braun, & van der Heijde, 2012), but a Cochrane review 
emphasizes the need for research on the long-term safety of biological agents (Singh et al., 
2011). Anti-TNF therapy is recommended for patients with high disease activity (Braun et al., 
2011), but this treatment is not available to all patients due to concurrent or previous disease 
as well as showing low efficacy in some patients (Dougados & Baeten, 2011).  
Disease-modifying anti-rheumatic drugs (DMARDs) are commonly used in inflammatory 
disease such as RA. The use of these pharmaceuticals such as methotrexate and sulfasalazine 
have little effect on axial symptoms, and are only recommended in SpA patients who also 
present with peripheral disease symptoms (Chen, Veras, Liu, & Lin, 2013; Haibel & Specker, 
2009). 
Exercise has the potential to alleviate disease progress and reduce co-morbidity in patients 
with SpA. However, an empirical view that intensive exercise can increase disease activity in 
patients with a chronic, rheumatic disease has previously prevailed (Benatti & Pedersen, 
2015; Perandini et al., 2012). Results from studies of other chronic diseases (Pedersen & 
Saltin, 2006) and a recent randomized control pilot study (Sveaas et al., 2014) imply that a 
combination of endurance and resistance training can reduce the inflammatory process and 
possibly modify disease course. Combining both endurance and resistance training is 
presumably important as various modes of exercise induce different physiological response 
(Jonas, 2009).   
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2.1.4 SpA and body composition 
Several studies on patients with chronic inflammatory rheumatic diseases have reported an 
altered body composition in patients with RA. The observed changes in body composition 
have often been termed rheumatic cachexia (Engvall et al., 2008; Okcu, Yardimci, & 
Comoglu, 2002; Rall et al., 2002; Roubenoff et al., 1994). Cachexia is defined as “a complex 
metabolic syndrome associated with underlying illness and characterized with loss of muscle 
mass with or without loss of fat mass” (Evans et al., 2008, p. 794). The diagnostic criteria 
include weight loss of at least 5% in the last twelve months in concert with three of the 
following criteria: decreased muscle strength, fatigue, anorexia, low fat-free mass or abnormal 
biochemistry (Evans et al., 2008; Rolland, Abellan van Kan, Gillette-Guyonnet, & Vellas, 
2011). In an attempt to facilitate early detection of cachexia, a consensus paper by Muscaritoli 
et al. (2010) listed the following diagnostic criteria for detecting pre-cachexia: an underlying 
chronic disease, unintentional weight loss ≤5% the last six months, chronic or systemic 
inflammatory response and a reduced desire to eat. Even though some studies report a 
prevalence of rheumatoid cachexia in a majority of the patients (Engvall et al., 2008; Rall et 
al., 2002), a study by van Bokhorst et al. (2012) did indeed observe significant alterations in 
body composition in their patient population, although only 1% of the cohort fit the diagnostic 
criteria of pre-cachexia or cachexia. The authors further question the relevance of the 
imperative criteria of involuntary weight loss and anorexia-related symptoms in diagnosing 
rheumatoid cachexia. In patients with RA, a reduction in lean body mass (LBM) is often 
accompanied by a maintained or increased fat mass (FM), resulting in a relatively stable body 
weight (Rajbhandary, Khezri, & Panush, 2011).  
Etiology of rheumatoid cachexia is considered to be multi-factorial, and an excessive cytokine 
production is indicated as one of the underlying mechanisms (Rall & Roubenoff, 2004). The 
hypothesized catabolic effect of increased circulating levels of inflammatory cell signaling 
molecules is indicated in a cross-sectional study by Arshad et al. (2007), where loss of fat-free 
mass was associated with high disease activity. Physical inactivity due to pain and stiffness, 
resulting in reduced muscle mass and strength, is also implicated as a plausible factor 
underlying rheumatoid cachexia. Additionally, alterations in hormone level have been 
suggested as a possible etiological factor. Rall et al. (2002) found no difference in growth 
hormone (GH) kinetics between RA patients and controls when adjusting for difference in fat 
mass. Insulin-like growth factor 1 (IGF-1) tended to be lower in RA patients, but this 
difference was non-significant (p= 0.08). Insulin can inhibit muscle protein degradation, and 
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an association between reduced peripheral insulin action in inflammatory arthritis and a 
catabolic milieu, is hypothesized as a potential factor contributing to rheumatoid cachexia 
(Rall & Roubenoff, 2004; Roubenoff, 2009). 
Regarding SpA, there are a few cross-sectional studies comparing body composition in 
patients to healthy controls. Marcora et al. (2006) observed lower appendicular and total LBM 
in AS patients, but no difference in FM. These results coincide with the reduced LBM 
detected in a study with a larger population, although those body composition estimates were 
predicted by methods of lower validity (Giltay, van Schaardenburg, Gooren, Kostense, & 
Dijkmans, 1999). Sari et al. (2007) report a lower FM, but no difference in fat free mass index 
in a male AS population when measured by bioelectrical impedance analysis (BIA) and 
skinfold thickness. Contrasting these results, Toussirot el al. (2001), Toussirot et al. (2007), 
Dos Santos et al. (2001) and Plasqui et al. (2012) observed no significant divergence in FM or 
LBM between AS patients and healthy age- and sex-matched controls. Different methods of 
measuring body composition are used in the mentioned studies, thus making direct 
comparisons of results somewhat challenging (Leahy, O'Neill, Sohun, & Jakeman, 2012). 
Furthermore, study inclusion varies in disease classification criteria. Included study 
participants also differ in disease duration (range: 8.4±6.3 years to 22±11 years), although 
self-reported disease activity is somewhat similar (BASDAI range: 3.43±1.82 to 5.2±2.2, not 
measured in Giltay et al. or dos Santos et al.). In summary, considering the disparate results, 
the impact of systemic inflammation in SpA on body com remains uncertain. As emphasized 
by Plasqui et al. (2012), there is a lack of studies concurrently examining body composition 
and local muscle mass. 
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Table 1. Studies evaluating body composition in SpA patients. 
Author Aim of study N 
(age 
mean±SD) 
Measured variables Results Conclusion Comment 
Dos 
Santos et 
al. 
(2001) 
Examine 
regional 
distribution of 
bone mass to 
seek factors 
leading to bone 
loss in AS 
39 male AS 
patients 
(37.6±9.1), 39 
controls from 
a population 
of military 
police 
civilians, age-
matched. 
Demographic data, 
CRP, ESR, markers 
of bone loss, pelvic 
and thoracolumbar 
radiographs, DXA, 
questionnaire on 
physical activity and 
calcium intake 
Controls significantly 
heavier (75.6±10.4 kg vs 
AS 69.3±12.1 kg, 
p<0.01). No significant 
difference in FM or 
LBM. Lumbar spine 
BMD lower in AS 
(1.085±0.178 vs. 
1.232±0.136 g/cm2, 
p<0.01). 
AS is associated 
with bone loss, but 
does not affect 
main variables of 
BC. 
Control group 
may not be 
representative to 
the AS 
population.  
Giltay et 
al.  
(1999) 
 
Compare serum 
levels of CK + 
other 
biochemical 
markers related 
to skeletal 
muscle between 
AS patients and 
healthy controls 
58 AS 
patients (48, 
range 28-
70), 60 age 
+ sex- 
matched 
controls 
Demographic data, 
current use of 
medication, total 
energy food intake 
by food 
questionnaire, non-
fasting blood 
samples, estimation 
of LBM by formula 
validated against 
BIA 
AS: significantly 
lower serum levels of 
CK+ other 
biochemical markers. 
AS patients decreased 
LBM (55.8 vs 59.2 
kg, p= 0,004). AS:  
negative correlations 
between CRP and CK 
(r=-0.48, p<0.001) 
and aldolase (r=-0.37, 
p=0.005) 
Results suggest 
decreased 
circulating 
markers of 
skeletal muscles 
in AS patients 
No control for 
PAL. Estimation 
of LBM from age, 
sex and height: 
limited value, 
formula may not 
apply to AS 
patients (lower 
height due to 
kyphosis)  
Marcora et 
al.  
(2006) 
Determine loss 
of appendicular 
LBM in AS 
patients with 
long disease 
duration 
19 male AS 
patients, 
(53±12), 19 
age-matched 
controls 
Demographic data 
including knee 
height, BASDAI, 
BASFI, pelvic 
radiograph, ESR, 
CRP, PAL 
questionnaire, DXA, 
MVC isokinetic 
knee extension at 
60°/sec, grip 
strength, 30-second 
sit-to-stand chair test. 
12% reduction 
appendicular LBM (p= 
0.005), 11% reduction 
total LBM (p= 0.002), no 
difference total BMD, 
total FM or trunk fat. 
MVC knee extensor 
lower in AS (181±67 
Nm) vs controls (228±72 
Nm, p=0.040).  
Appendicular LBM 
correlated with MVC 
knee (R= 0.79, p<0.001) 
Preliminary 
evidence of 
cachexia in AS 
patients. 
Not matched for 
PAL – difference 
in PAL 
approached sign 
(p= 0.052), 
however small 
biological 
difference. No 
measure of diet.  
A priori sample 
size calculation. 
Control for 
sarcopenia by 
age-matching. 
Plasqui  et 
al.  
(2012) 
Compare BC, 
daily PAL + 
relationship 
between BC, 
serum TNF and 
PAL  
 
25 patients 
(48 ±11), 25 
healthy 
controls,  
age-, sex- 
and BMI- 
matched 
Demographic data, 
body water by 
deuterium dilution, 
body volume by air-
displacement 
plethymography. 
PAL: Triaxial 
accelerometer 7 
days. VO2max test. 
CRP, serum TNF, 
BASDAI 
Height lower in patients 
(171 vs 177 cm, p=0.01) 
No difference FM or 
FFMI, nor 
accelerometer output. 
Inverse relationship 
between CRP and 
PAL (R= -0.39, 
p<0.01). No 
correlation between 
serum TNF and FFMI 
or BASDAI and 
LBM. 
AS equally 
healthy to 
controls. 
Indicates a need 
for studies 
examining 
muscle mass at 
a local level. 
First study with 
objective 
measurement of 
daily PAL in this 
patient group. 
High validity 
level of 
measurement 
techniques. 
Possible selection 
bias – recruited 
patients with 
moderate to high 
PAL?  
No difference in 
TNF levels 
between patients 
and controls could 
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imply AS study 
population does 
not have severe 
disease.  
Sari et al. 
(2007) 
Evaluate effect 
of inflammation 
on insulin 
resistance, 
serum leptin 
levels and BC 
28 AS 
patients (31, 
range 20-51 
yrs), 17 
healthy age-
matched 
controls 
Demographic data, 
insulin and leptin 
levels, ESR, CRP, 
BASDAI, BASMI, 
BASFI, BIA, SFT 
BIA measures: FM lower 
in AS men (10.1 %, 
range 3.8-23.7%) vs 
controls (18.6 %, range 
8.1-24%), p<0.05. No 
difference in FFMI. 
Serum leptin lower in AS 
(6.011 vs. 10.924, p= 
0.02) 
Inflammation in 
AS can reduce FM 
and serum leptin 
levels  
Low serum leptin 
possibly 
correlated with 
low FM. No 
match for PAL. 
BIA and SFT are 
not reference 
methods for 
evaluating BC. 
Toussirot 
et al.  
(2001) 
Examine BMD 
and determine 
influence of AS 
on BC  
 
71 AS 
patients 
(39.1±11.5), 
71 healthy 
controls, age- 
and sex-
matched. 
Demographic data, 
BASDAI, ESR, 
CRP, BMD femoral 
neck, total body 
DXA, ultrasound 
right calcaneus 
No difference LBM or 
FM.  BMD decreased in 
AS vs controls at lumbar 
spine (1.08±0.17 g/cm2 
vs. 1.18±0.13 g/cm2, 
p=0.0002) and femoral 
neck (0.97±0.16 g/cm2 
vs. 1.04±0.13 g/cm2, 
p=0.01) 
AS patients 
decreased BMD at 
spine and femur, 
AS disease has no 
influence on soft 
tissue. 
Did not include 
patients with criteria 
of severe disease. No 
record of medication 
or PAL. Significant 
difference in height 
(AS 169.1 cm vs. 
controls 172.5 cm, 
p= 0.02) 
Toussirot 
et al.  
(2007) 
Examine 
adipose tissue in 
AS patients to 
evaluate 
contribution of 
fat-derived 
molecules to 
inflammatory 
response 
 
53 AS 
patients, 
(44.1±0.6), 35 
healthy 
controls, 
matched for 
age, sex and 
PAL 
questionnaire  
Demographic data, 
BASDAI, BASFI, 
daily calorie intake, 
ESR, CRP, total 
body DXA, serum 
TNF, ghrelin3, 
adiponectin4, leptin5, 
growth hormone, 
IGF-16, IGFBP-37 
No sign. difference LBM,  
FM, IGF-1, growth 
hormone or level of 
adiponectin. Leptin 
decreased in AS (7.6±1.3 
ng/mL vs. 10.3±1.5 
ng/mL, p=0.006). Grehlin 
increased in AS 
(1365.5±81.5 pg/mL vs. 
1008.2±82.5 pg/mL, 
p=0.001), IGFBP3 
decreased in AS (2.6±0.1 
µg/mL vs. 3.1±0.1 
µg/mL, p<0.0001) 
AS patients no 
change in FM. No 
clear association 
between 
adipokines and 
markers of disease. 
Decreased 
IGFBP-3 can 
inhibit IGF-1 
activity and 
negatively effect 
LBM..  
Match for PAL 
based on 
questionnaire 
estimating VO2max, 
no assessment of 
level of strength 
training. No record 
of weight or height in 
demographic data, 
only BMI. 
Decreased leptin – 
a possible 
mechanism to bar 
inflammation. 
AS: Ankylosing Spondylitis. BASDAI: Bath Ankylosing Spondylitis Disease Activity Index. BASFI: Bath Ankylosing 
Spondylitis Functional Index BASMI: Bath Ankylosing Spondylitis Metrology Index BC: Body Composition BIA: 
Bioelectrical Impedance Analysis. BMD: Bone Mineral Density. BM: Body Mass. BMI: Body Mass Index. CK: Creatine 
Kinase CRP: C-reactive protein. DXA: Dual energy X-ray absorptiometry ESR: Erythrocyte Sedimentation Rate. FFMI: Fat 
Free Mass Index. FM: Fat Mass. LBM: Lean Body Mass. MVC: Maximal voluntary contraction. PAL: Physical Activity 
Level. SFT: Skin Fold Thickness. TNF: Tumor Necrosis Factor.  
 
 
  
                                                 
3 Ghrelin is a hormone that induces the release of growth hormone and stimulates appetite (Sato et al., 2012). 
4 Adiponectin is an anti-inflammatory adipokine (adipose-tissue derived cytokine) involved in regulating blood 
glucose levels and fatty acids breakdown by improving insulin sensitivity (Li, Wang, & Miao, 2011) 
5 Leptin is an adipokine involved in downregulating food intake and enhancing energy expenditure. Levels are 
highly correlated to FM. May play a pro-inflammatory role in modulating immune response (Otero et al., 2005; 
Scotece et al., 2014) 
6 IGF – see chapter 1.3.3 
7 IGFBP3 is the main IGF-1 binding protein (Toussirot et al., 2007) 
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2.1.5 SpA, muscle function and muscle morphology 
In addition to joint pain and stiffness, muscle pain and tenderness is a common feature of 
SpA. The source of muscle pain has been attributed to inflammation in joints and 
enthesopathy. However, patients with SpA commonly experience considerable relief of pain 
and stiffness following exercise, possibly indicating a direct involvement of the muscle itself 
in SpA (G. O. Hopkins, J. McDougall, K. R. Mills, D. A. Isenberg, & A. Ebringer, 1983). 
Studies have demonstrated reduced muscle strength and increased muscle fatigue in AS 
patients in a non-active period of disease compared to age- and sex-matched healthy controls 
(Sahin, Ozcan, Baskent, Karan, Ekmeci, et al., 2011; Sahin, Ozcan, Baskent, Karan, & 
Kasikcioglu, 2011). In contrast, a small-sample study observed significantly reduced objective 
physical function, but no difference in quadriceps strength between AS patients and controls 
(Matschke, Jones, Lemmey, Maddison, & Thom, 2013). Faus-Riera et al. (1991) assessed 
muscle pathology in 30 patients with AS and 22 controls by means of questionnaire regarding 
musculoskeletal pain, physical exercises, strength measurements, EMG and biopsy of mm. 
quadriceps femoris, the latter only performed on 24 patients and five controls. They detected 
mild histological abnormalities in 66.7% of the biopsies yielded from patients, but conclude 
that the observed morphological changes are a consequence of pain inhibition and reduced 
activity rather than the inflammatory process. Carrabba et al. (1984) performed a case series 
study where they found signs of atrophic angulated fibers and a modest prevalence of type 1 
fibers in muscles close to the spine in a sample of eight AS patients. Normal histological and 
histochemical measures in the deltoid muscle was observed in a small subsample of the 
patients, and the morphological difference in paraspinal muscle was interpreted as being 
related to axial inflammation. A 30-year old study including 20 AS patients and no controls 
revealed histological and electromyographic changes in the quadriceps femoris muscle, and 
indicated a need for further studies concerning the underlying mechanisms (Hopkins, 
McDougall, Mills, Isenberg, & Ebringer, 1983). The aforementioned studies assessing muscle 
morphology in SpA are dated, and the disease manifestations in studied patients may differ 
from what we encounter in our present-day clinical practice due to modern therapeutic 
options. To our knowledge, there is a paucity of novel studies addressing this topic. However, 
a study published in 2012 (Beenakker et al.) assessed the influence of chronic systemic 
inflammation on muscle characteristics in 10 patients with RA, by comparing biopsies from 
m. vastus medialis to biopsies yielded from a population of 27 individuals with osteoarthritis 
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(OA). They found no significant difference in muscle fiber distribution, level of lipofuscin8 or 
ratio of satellite cells, although the latter factor was only studied in a subsample due to limited 
biomaterial. The authors emphasize that anti-inflammatory medication or low-grade 
inflammation in OA patients may have tempered the studied variables. Additionally, there are 
several other histochemical factors known to regulate muscle growth and function that were 
not included in this study.  
In summary, decreased muscle strength in patients with AS may be due to pain, stiffness and 
inactivity. Inflammation raises stimulation from agents that can cause muscle protein 
catabolism, thereby potentially affecting muscle mass and loss of strength (Sahin, Ozcan, 
Baskent, Karan, & Kasikcioglu, 2011). Thus, it seems unclear whether the muscle 
abnormalities observed in SpA patients are related directly to the underlying inflammation or 
indirectly through pain, stiffness and reduced levels of physical activity.  
2.2 Skeletal muscle 
Skeletal muscle is the most abundant tissue in the human body with a primary function of 
producing movement and maintaining posture, in addition to a role as a metabolic regulator. 
Muscle mass can vary between individuals due to genetic, physiological and pathologic 
qualities (Schiaffino, Dyar, Ciciliot, Blaauw, & Sandri, 2013). In a large sample, cross-
sectional study that employed whole body magnetic resonance imaging (MRI), skeletal 
muscle mass was estimated to 38.4% of relative total mass in men, which was significantly 
higher than the 30.6 % observed in women (Janssen, Heymsfield, Wang, & Ross, 2000). 
Skeletal muscle mass can be measured by several methods, and Dual energy X-ray 
absorptiometry (DXA) calculation of  LBM corrected for body height has been proposed as a 
valid indicator of muscle mass (Andreoli, Scalzo, Masala, Tarantino, & Guglielmi, 2009; 
Toombs, Ducher, Shepherd, & De Souza, 2012). Data from the NHANES9 study provide 
DXA-derived body composition reference curves for individuals with an age range of 8-85 
years (Kelly, Wilson, & Heymsfield, 2009). Applying to the population included in our study, 
median reference values for total LBM/height2 for white males aged 30-45 years are estimated 
to 18.43-18.78 kg/m2 when measured with GE Healthcare Lunar DXA systems (Fan et al., 
2014). 
                                                 
8 Lipofuscin is a marker for oxidative damage 
9 National Health and Nutrition Examination Survey: data collected from 1999-2004 
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2.2.1 Muscle fibers: Structure and function 
The smallest functional unit of movement is the motor unit, defined as “an α-motoneuron plus 
the muscle fibers it innervates” (Lieber, 2010, p. 76). Muscle fibers within one motor unit are 
of the same phenotype and distributed throughout a region of the muscle. Studies on both 
animals and humans have shown that slow-contracting motor units are recruited at low levels 
of voluntary effort. When tension increases, faster motor units are drafted (Lieber, 2010).  
Skeletal muscle fibers are heterogeneous, and have historically been classified using different 
schemes. In our study, different muscle fiber types are defined by immunohistochemical 
properties. This form of fiber-typing scheme uses antibodies that identify what type of myosin 
heavy chain (MHC) molecule dominates within the different muscle fibers (Lieber, 2010). 
Bottinelli et al. (1996) divided muscle fibers into five types based on MHC isoforms: type 1 
alone, type 1/type 2A, type 2A, type 2A/2X, and type 2X. In terms of physiological function, 
muscle fibers are often classified as type 1, type 2A and type 2X, with the former often called 
slow-twitch fibers, and the latter two fast-twitch fibers. Different muscle fiber types appear to 
generate the same amount of peak isometric tension (Fitts & Widrick, 1996), although a dated 
study performed on tibialis anterior motor units in cats indicate that fast motor units have the 
potential of creating slightly more specific tension compared to slow units (Bodine, Roy, 
Eldred, & Edgerton, 1987). Fibertype distribution is however more consistently correlated 
with contraction time. Type 2A fibers are considered twice as fast as type 1, while type 2X is 
3-4 times as fast as type 1 (Aagaard & Andersen, 1998; Raastad, Paulsen, Refsnes, 
Rønnestad, & Wisnes, 2010). Since power output is a function of force and velocity, muscles 
with a predominance of fast-twitch fibers can generate more power compared to muscles with 
an abundance of slow-twitch fibers. Fibertype distribution differs between various muscle 
groups as well as among individuals. The latter is exemplified by the observation of a larger 
volume of type 1 fibers in highly endurance-trained athletes compared to strength athletes 
(Wilson et al., 2012). Morphological properties of different muscle fiber types pertain to the 
metabolic differences one can observe between fiber types. Slow-twitch fibers have a larger 
concentration of oxidative enzymes, a necessity for oxidative phosphorylation. Due to a 
higher concentration of glycolytic intermediates in the cytoplasm, fast-twitch fibers have a 
better glycolytic capacity (Lieber, 2010). The number of repetitions achieved at submaximal 
resistance exercise is considered to partly reflect fiber type distribution (Andersen & Aagaard, 
2010). However, a small study (n= 12 male physical education students) by Terzis et al. 
(2008) observed a non-significant correlation coefficient between fiber composition and 
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number of leg press repetitions at 70% 1RM and a high correlation (r= 0.70, p= 0.01) between 
m. vastus lateralis capillary density and number of repetitions. 
Muscle capillaries are arranged parallel to muscle fibers, and the amount of capillaries reflect 
the capacity for oxygen delivery from the blood to the muscle cell. Exercise can lead to an 
increase in maximum oxygen uptake (VO2max) due primarily to changes in maximum cardiac 
output. At the peripheral level, an exercise-induced rise in capillary density accommodates for 
elevated blood flow rates by maintaining transit time for each red blood cell within the 
capillary wall (Bassett & Howley, 2000). Ratio of capillary to muscle fiber can be assessed in 
muscle biopsies and is proposed to be proportionate to muscle cell mitochondrial volume 
(Mathieu-Costello & Hepple, 2002). Capillary density is highest in oxidative fibers with 4.2 
and 4.0 capillaries per fiber for type 1 and 2A respectively. Type 2X is reported to have a 
slightly lower capillary density of 3.2 (Egan & Zierath, 2013). 
Nestled between myofibrils, mitochondria, often referred to as the cell’s powerhouse, are 
cellular organelles with genetic material (mDNA) independent to cellular DNA. The amount 
of cellular mitochondria is a balance between mitochondrial synthesis (biogenesis) and 
mitochondrial degradation (mitophagy) (Russell, Foletta, Snow, & Wadley, 2014). Endurance 
exercise can increase the number of mitochondria through biogenesis, as well as improve 
function of the existing mitochondria pool (Yan, Lira, & Greene, 2012). Counterbalance 
between mitochondrial division (fission) and fusion controls mitophagy, an inherent process 
in the removal of damaged mitochondria. However, stress conditions may alter the rate of 
mitophagy. Mitochondrial deficiency can lead to clinical symptoms such as reduced exercise 
tolerance, fatigue and an advanced production of lactic acid (Hood et al., 2003). In addition to 
a prime role in synthesizing adenosine triphosphate (ATP) through the electron transport 
chain, mitochondria can function as signaling platforms for other cellular processes and their 
action is highly responsive to alterations in cellular morphology and metabolism (McBride, 
Neuspiel, & Wasiak, 2006). For instance, mitochondria can release factors that are involved in 
the process of apoptosis10 (Lanza & Sreekumaran Nair, 2010). The two opposing processes of 
life-promoting ATP production and cell death rely on a mitochondrial enzyme termed 
Cytochrome C oxidase (COX). COX transports electrons in the electron transport chain and is 
pivotal in the production of ATP. To the contrary, cytoplasmic translocation of COX is 
                                                 
10 Apoptosis is the process of cell death (Lieber, 2010) 
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associated with increased generation of reactive oxygen species (see chapter 1.3.5) and 
apoptosis (Huttemann et al., 2011; Y. Li, Park, Deng, & Bai, 2006).   
2.2.2 Satellite cells 
Myonuclei are incapable of mitosis, and additional nuclei in the muscle fiber are added 
through recruitment of satellite cells. Also known as myogenic precursor cells, satellite cells 
are allegedly dormant cells that reside on the surface of the muscle fiber, underneath the basal 
lamina (Mauro, 1961). Signals for satellite cell activation can be triggered through processes 
aimed at maintaining muscle fiber homeostasis, in hypertrophic pathways and in regeneration 
after muscle cell injury. The latter process involves proliferation of satellite cells that evolve 
into myotubes and further mature to new muscle fibers. In addition to having the ability to 
breed into a different cell type, satellite cells are also capable of self-renewing by proliferation 
of daughter cells, hence fitting the description of a stem cell (Kadi et al., 2005; Zammit, 
Partridge, & Yablonka-Reuveni, 2006).  
Volume and function of satellite cells is controlled by several complex intrinsic and extrinsic 
cellular signaling pathways (Shadrach & Wagers, 2011). A study by Kadi et al. (2004) on 31 
young and 27 elderly men and women observed a reduction in the satellite cell pool with 
increasing age, but no significant gender difference. Relative amount of satellite cells pr. 
muscle fiber was 6.9% in young men and 7.1% in young women, in contrast to the 3.9% and 
4.1% observed in the elderly men and women respectively. The results of the aforementioned 
study contrasts the non-significant age difference in satellite cell population observed in a 
study by Roth et al. (2000) on 14 young and 15 elderly individuals. Furthermore, the latter 
study noted a much lower proportion of satellite cells (1.7-2.8%).  Discrepant results can be 
explained by factors such as divergent levels of physical activity between the study 
participants, use of different analyzing methods, as well as possible morphological differences 
between the two muscles (m. tibialis anterior; m. vastus lateralis) that were investigated.  
Some authors argue that human studies show positive adaptations in satellite cell population 
in response to exercise, although it is unclear if this response is affected by type of exercise 
protocol (Kadi et al., 2005). Schiaffino et al. (2013) describe how an acute stimulus, such as 
an injury or eccentric contractions, can trigger activation and differentiation of satellite cells, 
thus contributing to muscle fiber growth and regeneration. Contrary to this pathway, exercise 
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with more moderate loads is suggested to be associated with a growth response resulting from 
an increased protein synthesis. 
2.2.3 Factors that determine muscle fiber size 
Myofiber size depends on the sum of myofibrils within the fiber. Myofibrillar hypertrophy is 
associated with an increase in the number of contractile proteins actin and myosin. In contrast, 
muscle fiber atrophy is a result of a down-regulation of protein synthesis and an increase in 
protein degradation. Muscle fiber growth is also aided by addition of cell nuclei through the 
recruitment of satellite cells, thereby maintaining a hypothesized myonuclear domain ceiling 
of ~2000 µm2 (Lieber, 2010; Petrella, Kim, Mayhew, Cross, & Bamman, 2008; Sandri, 2008).   
Insulin Growth Factor-1 (IGF-1) is a hormone produced in the liver as well as in target 
tissues. Autocrine secretion of IGF by muscle cells is assumed following stimuli such as 
muscle injury or exercise, while paracrine secretion of IGF-1 by macrophages and endothelial 
cells rapidly increase following damage to myofibers. Endocrine secretion of IGF-1 may also 
partake, however, studies indicate that the role of circulating IGF-1 in muscle regeneration is 
modest (reviewed in: Zanou & Gailly, 2013). With a molecular structure similar to insulin, 
IGF-1 functions as a docking station for signaling enzymes that are involved in catabolic or 
anabolic muscle pathways (Clemmons, 2009). IGF-1 induces muscle hypertrophy trough the 
PI-3K/Akt pathway. PI-3K is an enzyme, which when activated triggers recruitment of Akt 
kinase. This pathway is suggested to separate into several branches that may be involved in 
hypertrophy signaling, with the activation of mammalian target of rapamycin (mTOR) 
identified as a significant mediator of protein synthesis. IGF-1 may also incite action through 
the mitogen-activated protein kinase/extracellular signal-regulated (MAPK/ERK) pathway11 
(Rommel et al., 2001; Schiaffino et al., 2013; Zanou & Gailly, 2013). Factors such as 
inflammation, disease, malnourishment and various pharmaceuticals may decrease cellular 
content of IGF-1 mRNA and reduce IGF-1 synthesis (reviewed in: Clemmons, 2009; 
Schiaffino et al., 2013). 
Stimuli from exercise or injury can prompt different splicing of the IGF-1 gene. Translation of 
one of the mRNA species is hypothesized to mature into a chain of amino acid molecules that 
deviates from the mature IGF-1 protein. This IGF-1Ec (IGF-1Eb in rodents) isoform has been 
                                                 
11 Primary response of MAPK activation is growth, remodeling, transcription (Powers, Ji, Kavazis, & Jackson, 
2011) 
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labeled mechano-growth factor (MGF) (Dai, Wu, Yeung, & Li, 2010). Based on in vitro 
studies on C2C1212 mouse cells, up-regulation of MGF is indicated in playing a role in 
satellite cell proliferation and activation. Levels of MGF subside while levels of IGF-1 
increase in the differentiation phase of muscle cell regeneration or growth, suggesting that 
MGF opposes muscle cell differentiation (Yang & Goldspink, 2002). These results concur 
with the observation of enriched levels of satellite cells following the addition of MGF to 
human primary muscle cell cultures derived from healthy and diseased subjects (Ates et al., 
2007). Attempting to examine MGF-signaling in vivo, Philippou et al. (2009) detected a quick 
and transient increase in MGF, accompanied by an extended rise in IGF-1 following eccentric 
exercise. However, as reviewed by Matheny et al. (2010), levels of MGF are shown to be 
comparable to or even lower than IGF-1 in early phases of proliferation, thus one cannot 
dismiss the possibility that MGF poses as a confounding factor.  
Atrophy is associated with a decrease in muscle fiber size due to a loss of organelles, 
cytoplasm and protein content. Accelerated protein degradation is mainly a result of increased 
activity in a multi-enzymatic process known as the ubiquitin-proteasome pathway (Mitch & 
Goldberg, 1996; Sacheck, Ohtsuka, McLary, & Goldberg, 2004; Schiaffino et al., 2013). 
Ubiquitin are small heat shock proteins (see chapter 1.3.5) that link themselves to proteins 
that are to be degraded in the ubiquitin-proteasome pathway. Proteasomes are cellular 
organelles, whose main function is degrading proteins that are marked for destruction. 
Increased proteolysis occurs as a result of muscle regulations that lead to increased mRNA 
transcription of ubiquitin ligases such as atrogin-1/MAFbx and MuRF1, as well as raised 
levels of proteasomes (Sacheck et al., 2004; Sandri, 2008). This process is influenced by 
transcription factors known as Forkhead box O (FoxO). Four FoxO members are found in 
human skeletal muscle; FoxO1, FoxO3, FoxO4 and FoxO6, with the latter primarily found in 
the central nervous system (Sanchez, Candau, & Bernardi, 2014). FoxO1 and FoxO3 can 
inflate the transcription of ubiquitin ligases in the presence of factors known to induce atrophy 
(Lieber, 2010). On an opposite note, an increase in IGF-1/Akt signaling can translocate FoxO 
from the myonuclei to the cytoplasm (Sandri, 2008). Adenosine monophosphate-activated 
protein kinase (AMPK) activation is associated with increased nuclear translocation of  
FoxO1 and FoxO3, thus having an opposing effect to IGF-1/Akt (Sanchez et al., 2014). FoxO 
proteins are also involved in the autophagy-lysosomal pathway. Autophagy is a cellular 
                                                 
12 C2C12: mammalian skeletal muscle models that can be used to study molecular processes involved in cell 
proliferation and differentiation (Yang & Goldspink, 2002). 
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housekeeping process involving lysosomes; cellular subunits that break down organelles, 
protein substrates and damaged cell material. FoxO3 controls the transcription of several 
autophagy-dependent genes, while the role of FoxO1 in autophagy remains enigmatic 
(Mizushima & Komatsu, 2011; Sanchez et al., 2014; Sandri, 2008). FoxO proteins are further 
implicated in regulating mitochondrial ubiquitin ligases, potentially affecting mitochondrial 
autophagy (mitophagy) (Sanchez et al., 2014; Schiaffino et al., 2013). Moreover, FoxO 
proteins can negatively regulate muscle regeneration by inhibiting satellite cell activation 
(Sanchez et al., 2014).  
Myostatin, also known as GDF-8 (growth and differentiation factor 8), is produced by skeletal 
muscle and identified as a negative regulator of myogenic development and growth (reviewed 
in: Jespersen, Kjaer, & Schjerling, 2006). Myostatin can intercede post-natal hypertrophy by 
targeting satellite cell differentiation and proliferation through a process that results in a 
negative adjustment of myogenic transcription factors (MyoD, Myf-5, myogenin and Mrf4 
proteins) (Matsakas & Diel, 2005; Walsh & Celeste, 2005; Zanou & Gailly, 2013). In addition 
to inhibiting satellite cell contribution to muscle growth, myostatin may also have direct 
effects on myotubes. Zimmers et al. (2002) observed muscle and fat wasting after injecting 
high levels of circulating myostatin into the thighs of mice, controlling for the potential effect 
of myostatin in inducing anorexia. Furthermore, Trendelenbrug et al. (2009) demonstrated 
that increased myostatin expression is accompanied by reduced diameter of in vitro human 
skeletal muscle myotubes. The authors further hypothesize that instead of activating catabolic 
pathways, myostatin may play a role in inhibiting processes that promote protein synthesis. 
However, the consequence of myostatin expression in in vitro may differ from what happens 
in living organisms since hormonal and growth factors are difficult to replicate in cell 
cultures.  
2.2.4 Skeletal muscle, immune cells and inflammatory agents 
Skeletal muscle can produce and secrete various cytokines and proteins, and is identified as an 
endocrine organ (Pedersen, 2011). Walsh et al (2011) imply that exercise can promote long-
term anti-inflammatory effects. The effects are probably partly due to a training-induced 
reduction in visceral fat. In addition, each bout of exercise can induce a cytokine response that 
promotes an auto-inflammatory environment. Based on studies evaluating the effect of 
endurance training on inflammatory agents, the benefits of exercise on auto-inflammatory 
response are well established (Walsh et al., 2011). A systematic review aimed to explore the 
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potential effectiveness of resistance training on altering the serum concentration of certain 
cytokines. The meta-analysis supported resistance-training interventions in increasing 
adiponectin and decreasing leptin (see footnote 4 and 5) and serum CRP levels. Moderate to 
high levels of training duration, frequencies and intensities were necessary to provoke the 
changes in cytokine levels. Regarding TNF, there was a lack of significant changes following 
interventions with resistance training, possibly related to small sample sizes and low statistical 
power in the included studies (de Salles et al., 2010).  
 Circulating and local cytokine levels may fluctuate in response to internal and external stress 
factors. Examples of internal stress factors are hypoxia, mechanical stress, thermal stress, 
osmotic stress and oxidative stress as well as energy imbalance. External stress signals can 
indicate systemic stress and induce cellular responses (Welc & Clanton, 2013). 
Increased expression of TNF and other pro-inflammatory cytokines can cause insulin 
resistance and curtail the IGF-1/PI-3K/Akt hypertrophic pathway. Additionally, they may also 
play a role in activating the NF-κβ-pathway, a process implicated in increasing proteolysis 
(Peterson & Guttridge, 2008; Sandri, 2008; Zanou & Gailly, 2013).  NF-κβ transcription 
factors are usually kept in a dormant state by binding to an inhibitory protein called Iκβ. Pro-
inflammatory cytokines can trigger Iκβ, leading to nuclear translocation of NF-κβ. Activation 
of NF-κβ in turn induces gene transcription of proteins and enzymes involved in 
inflammatory processes, creating a positive feedback loop (Barnes & Karin, 1997).  
Inflammatory processes in skeletal muscle can rattle muscle homeostasis, although it is also 
recognized as a benign process in accelerating muscle repair and regeneration following 
injury or altered use. Generation of pro-inflammatory cytokines in inflamed muscle tissue 
leads to invasion of inflammatory cells such as neutrophils and macrophages. Neutrophils are 
white blood cells with a phagocytic function in clearing up damaged muscle fibers. However, 
neutrophil activation can release free radicals that can cause secondary harm to muscle tissue 
(Tidball, 2005). Succeeding the intrusion of neutrophils, macrophages are suggested to play a 
role in absorbing cellular debris. They can be divided into several subtypes that present at 
different times, suggesting that macrophages may have additional functions. For instance, 
macrophages are dense in pro-inflammatory cytokines, and macrophagal release of these 
cytokines may attenuate muscle regeneration. On the other hand, macrophages are also 
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implicated in helping satellite cells avoid apoptosis, thus possibly promoting muscle repair 
(Smith, Kruger, Smith, & Myburgh, 2008). 
2.2.5 Regulators of muscle fiber function 
Seeking to maintain normal cell function, muscle fibers can express heat-shock proteins 
(HSP) in response to elevated temperatures or other forms of physiological stress. HSP are 
also known as molecular chaperones and their expression is tissue-specific, with muscle fibers 
primarily displaying ATP-independent small HSPs as well as ATP-dependent HSP60, HSP70 
and HSP9013. In addition to protecting the cell by preventing protein misfolding and 
aggregation, HSPs are involved in cell signaling by acting as molecular chaperones in 
transporting enzymes and proteins to organelles (Z. Li & Srivastava, 2004; Liu & Steinacker, 
2001; Schlesinger, 1990). Ubiquitin is a small HSP expressed in muscle cells and is further 
commented on in chapter 2.2.3. Cellular stress can prompt translocation of a small HSP with a 
molecular weight of 27 kDA from the cytoplasm to the nucleus. The prime function of HSP27 
is to protect muscle cells against oxidative stress and prevent apoptosis (Dubinska-Magiera et 
al., 2014). Located in the mitochondria, HSP60 take part in the transport and assembly of 
mitochondrial protein that are encoded by nuclear DNA (Liu & Steinacker, 2001). Cellular 
volume of HSP60 is proposed to be comparative to mitochondrial content, with a concomitant 
increase in citrate synthase14 and HSP60 observed in rats after bouts of endurance exercise 
(Mattson, Ross, Kilgore, & Musch, 2000).  In response to cellular stress, levels of the HSP70 
family are inflated. Two forms of HSP70 are glucose-regulated (GRP75 and GRP78). GRP75 
act in transporting and folding proteins in the mitochondria (Liu & Steinacker, 2001), while 
GRP78 is expressed in the endoplasmatic reticulum and involved in protein folding (Z. Li & 
Srivastava, 2004).  HSC70 and HSP72 represent two other members of the HSP70 family. 
HSC70 are present in the cytoplasm in non-stressed conditions and act in maintaining 
intracellular homeostasis (Bozaykut, Ozer, & Karademir, 2014). However, a decrease in 
HSC70 was observed in the m. soleus during non-weight bearing in rats, implicating a 
possible role of HSC70 in regulating the rate of protein synthesis (Ku, Yang, Menon, & 
Thomason, 1995). Cytoplasmic synthesis of HSP72 is highly induced by heat. Besides aiding 
in transport of proteins to cellular compartments, HSP72 can prevent protein aggregation and 
promote refolding of partially folded proteins (Bozaykut et al., 2014). HSP90 constitutes 
another group of HSPs that are involved in stabilizing hormone receptors by binding to 
                                                 
13 Classification of HSP is based on molecular mass in kilodalton (kDa) 
14 Citrate synthase is an enzyme that is often used as a marker of undamaged mitochondria 
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unoccupied receptors and keeping them in a quiescent state. HSP90 are involved in cell cycle 
regulation by retaining proteins in a folded form (Bozaykut et al., 2014; Liu & Steinacker, 
2001; Sreedhar, Kalmar, Csermely, & Shen, 2004). 
In addition to various physiological stress, physical exercise also has the potential of 
stimulating level of HSPs in skeletal muscle. Furthermore, pro-inflammatory cytokines may 
influence the expression of HSPs , possibly increasing susceptibility to apoptosis (Liu & 
Steinacker, 2001). Schett et al. (2003) observed a temporal decrease of HSP 70 synthesis in 
cell cultures treated with TNF. As discussed by the authors, a transient down-regulation of 
synthesis may curb the anti-apoptotic effect of HSP70. Increased levels of anti-HSP60 
antibodies are observed in SpA, although this elevation may primarily reflect an activation of 
the general immune response (Hjelholt et al., 2013). A dated review upholds that although 
antibodies against HSP have been observed in different inflammatory, rheumatic diseases, 
levels of anti-HSP antibodies do not differ greatly from healthy subjects and the role of anti-
HSP antibodies as a central autoimmune disease pathogen is unlikely (Tishler & Shoenfeld, 
1996). 
Metabolic processes produce small atoms or molecules called reactive oxygen species (ROS). 
Perturbations in cell redox state can lead to an increased production of ROS, potentially 
causing oxidative damage to muscle fibers. Superoxide and nitric oxide represent the prime 
ROS produced in cells. Superoxide is a mild oxidative, but can be catalyzed to form other 
biologically toxic ROS. Nitric oxide interacts with superoxide to produce an oxidizing agent 
named peroxynitrite. Superoxide dismutase (SOD) is one of three major antioxidant enzymes 
in cells, and protects the cell from the pro-inflammatory effects of superoxide by converting it 
to hydrogen peroxide and oxygen. Glutathione peroxidase (GPX) or catalase (CAT), two 
other antioxidant enzymes, then remove this (Afonso, Champy, Mitrovic, Collin, & Lomri, 
2007). The amount of antioxidant enzymes differ between fiber types, with the highest 
relative amount in type 1 fibers. Endurance training can increase the cellular level of SOD and 
GPX, while the effect of exercise on CAT is uncertain (reviewed in: Powers et al., 2011). In 
contrast, pro-inflammatory cytokines associated with various joint diseases are proposed to 
repress antioxidant enzymes, resulting in an increase in ROS (Afonso et al., 2007). A 20-year 
old study observed elevated levels of serum nitrate, a marker of nitric oxide production, in 
patients with active SpA (Stichtenoth, Wollenhaupt, Andersone, Zeidler, & Frolich, 1995). 
Notably, the patient population included only one patient with AS, with the remaining 
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possibly affected more by peripheral joint inflammation than axial inflammation. 
Contradictory results are reported in a study where no difference in levels of nitric oxide or 
SOD was observed between untreated AS patients with active or non-active disease compared 
to age- and sex-matched controls. However, the latter study noted significantly higher levels 
of CAT as well as malondialdehyde, a marker of oxidative stress, in patients with active 
disease compared to controls. These findings may indicate that oxidative stress is increased in 
AS patients with active disease (Ozgocmen et al., 2004).  
2.2.6 Possible effects of pharmaceuticals on body composition and muscle 
tissue 
Pharmaceuticals have potential side effects, and the following passage will discuss how some 
of the disease-modifying medication commonly used by SpA patients may have an effect on 
muscle tissue or body composition.  
As previously mentioned, use of NSAIDs are advocated as the basic medication for treatment 
of SpA. Long-term use of NSAIDs is associated with an increased risk of gastrointestinal and 
cardiovascular side effects (Braun et al., 2011). NSAIDs block cyclooxygenase (COX), and 
the various COX-inhibiting drugs are subgrouped based on their specificity to the main COX 
isoforms COX-1 and COX-2. Transcript of COX-1 increase following exercise, but is also 
bountiful at the constitutive level. Intramuscular level of COX-2 is low at rest, but increased 
expression is seen in response to stimuli such as injury or exercise. Common drugs such as 
ibuprofen and acetaminophen suppress both COX-1 and COX-2 and are considered to be non-
selective COX-inhibitors (Trappe & Liu, 2013). COX is an enzyme that synthesizes 
prostaglandins; hormone-like mediators that stimulate protein metabolism (Alaranta, 
Alaranta, & Helenius, 2008). Indeed, the results of a double-blind placebo-controlled study 
indicate that consumption of non-specific COX-inhibitors at a maximal over-the-counter daily 
is associated with attenuated protein fractional synthesis rate following a bout of eccentric 
strength exercise (Trappe et al., 2002). The study did not measure the long-term effect of drug 
use on muscle metabolism, but hypothesize that regular use of these pharmaceuticals may 
inhibit muscle hypertrophy. Contrary to this, a double-blind randomized controlled trial 
involving 12 weeks of strength training in OA patients, observed no difference in muscle 
mass (CSA) between patients on NSAIDs (ibuprofen) vs placebo drugs (Petersen et al., 2011). 
Furthermore, enhanced muscle volume and strength has been observed in a group of older 
adults consuming acetaminophen or ibuprofen in combination with 12 weeks of strength 
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training (Trappe et al., 2011). The researchers propose that chronic use of COX-inhibiting 
drugs can lead to adaptations that advocate skeletal muscle hypertrophy in older individuals. 
Nonetheless, both OA patients and the elderly participants may have trained harder due to the 
pain-relieving effect of NSAIDs, thereby potentially influencing study results. Ingestion of 
NSAIDs is further suggested to have a deleterious effect on satellite cell activation by 
suppressing growth factor signaling (Mackey, 2013). Paulsen et al. (2010) examined the 
influence of a COX-2 inhibitor (celecoxib) on recovery and regeneration following eccentric 
exercise and observed no group difference in the number of satellite cells. Contradictory 
outcomes are reported in the previously mentioned study on OA patients, where the number 
of satellite cells increased in the placebo group, but not in the patients ingesting a non-specific 
COX-inhibitor (ibuprofen) (Petersen et al., 2011). These results coincide with an observed 
blunting effect of NSAIDs (non-specific COX-inhibitor; indomethacin) on satellite cell 
response in male endurance athletes following a single bout of 36 km running (Mackey et al., 
2007). As concluded in a review article (Schoenfeld, 2012), there is a lack of compelling 
evidence showing that occasional use of NSAIDs has detrimental effects on muscle growth. 
However, the effect of long-time use is more elusive, particularly in regards to the possible 
effect on satellite cell activity. Mackey (2013) and Schoenfeld (2012) recommend a need for 
future research to elucidate the discrepant results as well as investigate the possible effects of 
age and training status on differential response to NSAIDs. 
Pharmaceutics that function antagonistically to TNF, a crucial cytokine in rheumatic disease, 
are a rather novel therapeutic option in SpA and there are few studies investigating the effect 
of these medicines on muscle tissue. A 1-year prospective study suggests an association 
between anti-TNF treatment and a small, but significant gain in body weight and lean mass 
without shifts in fat mass (Briot, Garnero, Le, Dougados, & Roux, 2005). The authors propose 
that the observed changes relate to a 15% transient increase in serum IGF-1. Results of this 
study should however be interpreted with caution due to the small study population and lack 
of control group. Additionally, TNF blockers may ease common SpA symptoms such as pain, 
stiffness and fatigue (Machado et al., 2013), enabling the patients to be more physically 
active. The same research group examined changes in body mass (BM) and body composition 
in a larger group of SpA patients receiving anti-TNF-therapy in a 2-year prospective study. 
Interestingly, they observed a significant gain in BM after year 1 and 2, due primarily to an 
increase in FM as well as a small, but significant increase in LBM (Briot, Gossec, Kolta, 
Dougados, & Roux, 2008). Furthermore, a subsequential protocol to a subsample of the SpA 
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cohort from Briot et al., 2008 used new DXA software enabling separation of abdominal fat 
into visceral and subcutaneous adipose tissue. They observed significant gain in both visceral 
and subcutaneous FM, further questioning the relationship between these changes and risk of 
CVD (Hmamouchi et al., 2014). Diet and level of physical activity were not assessed in the 
aforementioned studies and are possible confounders to alterations in body composition. 
Thus, it is hard to explain if the changes in body composition are due to specific effects of 
anti-TNF medication or an effect on general well-being, physical activity and diet. However, 
the results reported in Hmamouchi et al. (2014) concur with the observed shifts in FM in a 
smaller 2-year prospective study, where no parallel change was detected in self-reported diet 
or exercise habits (Toussirot et al., 2014). On an opposite note, studies assessing the effect of 
12 (Metsios et al., 2007) and 24 (Marcora, Chester, Mittal, Lemmey, & Maddison, 2006) 
weeks of anti-TNF medication in RA patients observed no significant changes in body 
composition. Collectively, the effect of TNF-blockers on body composition is conflicting and 
specific effects on muscle tissue appear uncertain.  
Table 2. Studies evaluating effect of anti-TNF therapy on muscle tissue/body composition. 
Values are mean (SD) unless otherwise noted. 
Author 
(year) 
Aim of study  n 
(age) 
Measured variables Results Conclusion  Comment 
Briot  et al. 
(2005) 
 
Evaluate change in 
body weight and 
BC in SpA 
patients receiving 
anti TNF therapy 
over 1 year 
19 SpA 
patients 
(range: 
21-71) 
Demographic data, 
VAS pain, BASDAI, 
BASFI, ESR, CRP, 
BC and BMD by 
DXA at baseline, 6 
months and 1 year. 
Bone remodeling 
including IGF-1 
At 6 months: BM: + 
2.6 (3.7) %, p= 0.0012, 
LBM: + 2.1 (4.5) %, 
p= 0.03. 
At 1 year: BM: + 3.4 
(4.69 %, p= 0.001, 
LBM: + 3.2 (4.2) %, 
p= 0.003.  
At 3 months: Increase 
in IGF-1: +15 (40) %, 
p= 0.04 
Suggest changes in 
BC are related to 
anti-TNF therapy 
Twelve patients 
previously treated with 
corticosteroids, three 
currently.  
No control group. 
No assessment of 
diet or PAL 
Briot et al. 
(2008) 
 
Evaluate change in 
body weight and 
BC in patients 
receiving anti TNF 
therapy (etanercept 
or infliximab) over 
2 years 
106 
SpA/AS/ 
PsA 
patients 
(38±11) 
Demographic data, 
VAS pain, BASDAI, 
BASFI, ESR, CRP, 
BC and BMD by 
DXA at baseline and 
once a year 
At 1 year:  
BM: +3.4 (5.9) %, p 
< 0.001, FM: 12.1 
(22.4) %, p< 0.001, 
LBM: 1.9 (5.2) %, p 
< 0.001. 
At 2 years: 
BM: +3.5 (7.1) %, p 
< 0.001, FM: 14.5 
(26.8) %, p< 0.001, 
LBM: 2.0 (5.6) %, p 
< 0.001. 
 Change between 
year 1 and 2 non-
sign. 
  
Increase in FM 
– recommend 
assessment of 
serum lipids in 
future studies 
Weight gain can 
be explained by 
specific effects 
of anti-TNF 
therapy and/or 
generic effects 
of inflammation 
control by anti-
TNF 
Standardized 
procedures.  
Possible confounder: 
increased PAL due to 
effect of medication on 
pain/stiffness. 
33.9% with 
previous intake of 
steroids, 1% with 
current intake. 
37.7% had no 
change in BM 
No specific analysis 
of fat distribution  
No control group 
(difficult to find) 
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Hmamao-
uchi et al. 
(2014) 
Evaluate changes 
in VAT and SAT 
visceral 
in patients with 
anti-TNF therapy. 
2-year prospective 
study.  
85 
(39.3±11.
4)- 
ancillary 
protocol 
to Briot et 
al. 2008 
Baseline, 6, 12 and 24 
months: waistline 
circumference, BM, 
BMI, VAT + SAT 
with DXA 
VAT: at 6 months 
13.2(20.5)%, p < 
0.0001, at 1 year 
22.2 (28.2)%, p < 
0.0001, at 2 years 
32.4 (36.6)%, p < 
0.0001;  SAT: at 6 
months 8.7(20.4)%, 
p < 0.0001, 1 year 
17.9 (29.4)%,, p < 
0.0001, at 2 years 
24.2 (38.3)%, p < 
0.0001. 
SpA patients 
initiating anti-
TNF-therapy 
leads to 
significant 
increase in VAT 
and SAT 
Effect of  anti-TNF 
treatment can increase 
well-being  
increased appetite.  
Ancillary protocol 
to published results 
– authors may have 
precipitated results? 
No assessment of 
diet or PAL 
Marcora et 
al. (2006) 
RCT: Evaluate 
effect of etanercept 
(TNF-inhibitor) on 
BC in patients 
with early RA.  
Randomized to 24 
weeks of 
etanercept or 
methotrexate 
26 
(54±11 
and 
50±15) 
Baseline, 12, 24 weeks: 
DXA, measures of 
physical function, 
DAS28, CRP, ESR, 
serum IGF-1, IGF-2, 
IGF-binding protein 3 
Transient increase 
of IGF-1 at week 
12, p< 0.01 
No significant 
change in BC. 
Secondary analysis 
6 months follow-up 
of patients who 
gained >3% BM: 
patients with 
etanercept gained 
more LBM (44% vs 
14%), p= 0.04 
Primary 
analysis shows 
no significant 
effect of TNF-
inhibitor on BC 
No assessment of PAL 
or diet 
Metsios et 
al. 
(2007) 
Evaluate effect of 
anti-TNF therapy 
on BC, PAL and 
protein intake 
20 RA 
patients 
(61.1± 
6.8) and 
12 healthy 
controls 
matched 
for age, 
sex, BMI 
Baseline, 2 and 12 
weeks: Indirect 
calorimetry, BIA, 
IPAQ, DAS28, ESR, 
CRP, serum TNF 
No significant 
change in LBM or 
FM. 
 
TNF-blockers 
lead to 
improved 
disease activity 
and physical 
function + 
increased 
protein intake 
and PAL 
BIA has lower validity 
than DXA 
Toussirot 
et al. (2014) 
Evaluate long-
term consequence 
of TNF inhibitors 
on BC + short-and 
long-term effects 
of drugs on 
adipokine 
production 
(associated with 
anti-inflammatory 
effects) Single-
center 2 year 
prospective study 
12 SpA 
patients 
(40.7±4.6)  
8 RA 
patients 
(60.5±3.4) 
 
Baseline, 1,3,6,12,18 
and 24 months: 
Demographic data, 
DAS28, HAQ, 
BASDAI, BASFI, 
ESR, CRP, venous 
blood samples 
(adipokines, ghrelin 
and insulin). DXA at 
baseline, 6, 12, 24 
months 
AS: gain total fat 
mass (p= 0.02), 
tendency for change 
in BM (p= 0.07). 
RA: significant 
changes for BMI 
(p= 0.05). 
AS + RA: Resistin 
levels decreased (-
22.4%, p= 0.01) 
 
TNF antagonists 
induce changes 
in fat mass; 
increased 
android fat – 
questions the 
impact of anti-
TNF medication 
on 
cardiovascular 
risk 
Total-body 
composition scan.  
Long duration, 
repeated measurements              
Small study sample 
Possible confounder: 
other medication 
(allowed to take 
corticosteroids, 
DMARDs, NSAIDs)  
Lack of control 
group 
AS: Ankylosing Spondylitis. BASDAI: Bath Ankylosing Spondylitis Disease Activity Index. BASFI: Bath Ankylosing 
Spondylitis Functional Index BC: Body Composition BIA: Bioelectrical Impedance Analysis. BMD: Bone Mineral Density. 
BM: Body Mass.  BMI: Body Mass Index. CRP: C-reactive protein DAS28: Disease Activity Score in 28 joints. DXA: Dual 
energy X-ray absorptiometry ESR: Erythrocyte Sedimentation Rate. FM: Fat Mass. HAQ: Health Assessment 
Questionnaire. IPAQ: International Physical Activity Questionnaire. LBM: Lean Mass. PAL: Physical Activity Level. PsA: 
Psoriasis Arthritis. RA: Rheumatoid Arthritis. SAT: Subcutaneous adipose tissue. SpA: Spondyloarthritis. TNF: Tumor 
Necrosis Factor. VAS: Visual Analog Scale. VAT: Visceral adipose tissue. 
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Use of oral glucocorticoids, for example Prednisone, was defined as an exclusion criterion in 
our study. Glucocorticoids stimulate proteolysis and hinder protein synthesis, with a net 
catabolic effect that can lead to muscle atrophy (Mitch & Goldberg, 1996; Pereira & Freire 
de, 2011). Muscles with a predominance of fast fibers are more vulnerable to glucocorticoid-
induced atrophy, while slow-twitch fibers are less susceptible (reviewed in: Schakman, 
Kalista, Barbe, Loumaye, & Thissen, 2013). There has been some uncertainty regarding the 
mechanisms governing glucocorticoid influence on muscle mass. A randomized, cross-over 
trial observed higher fasting glucose, amino acids, glucagon and insulin following short-term 
use of Prednisone vs. placebo. The authors suggest that the results implicate a blunting effect 
of glucocorticoids on the anabolic response to insulin (Short, Bigelow, & Nair, 2009). 
Occasionally used, medical treatment by use of systemic corticosteroids for SpA is not 
supported by evidence (Braun et al., 2011).  
2.2.7 Mm. Quadriceps femoris 
Encompassing m. vastus medalis, m. vastus lateralis, m. vastus intermedius and m. rectus 
femoris, mm. quadriceps femoris (QF) consists of rather short muscle fibers with high 
pennation15 angles. Due to a large physiological CSA, QF is well suited in generating large 
forces (Lieber, 2010). Samples from the mm. vasti at the distal thigh of Caucasian cadavers 
indicate a considerable between-subject variability regarding vasti CSA, as well as an 
observation that each element of the vasti contributes to about one third of total vastus CSA. 
Moreover, the study investigators found a fused muscle mass in the distal part of QF in 30% 
of the cadavers, indicating that biopsies taken from m. vastus lateralis are susceptible to being 
interspersed with samples from m. vastus intermedius (Willan, Ransome, & Mahon, 2002).  
QF, and more specifically m. vastus lateralis, is frequently used in research work as the 
preferred biopsy site in the lower extremities. Muscle biopsies play an important role in 
evaluating disease that may affect muscle tissue, and can be performed by open or needle 
technique (Mikell, Chan, Stein, Tanji, & Winfree, 2013). M. vastus lateralis is recognized as 
safe since main nerves and blood vessels are far away from the location of the biopsy, the site 
is tolerated well by study participants and there are limited cosmetic issues (Meola, 
Bugiardini, & Cardani, 2012; Mikell et al., 2013).  
                                                 
15 Pennation angle: muscle fiber angle relative to the force-generating axis (Lieber, 2010) 
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Containing both slow- and fast-twitch fibers, m. vastus lateralis is a mixed striated muscle 
with a pooled estimated (mean±SD) 3.630±114 µm2 fiber CSA and 50.3±1.9% type 1 fiber 
distribution in healthy individuals over 40 years old (Gouzi et al., 2013). For younger male 
individuals (21.5±2.4 years), the muscle fiber type distribution is reported to hierarchically 
descend from 2A>1>2X and CSA approximates to 4844±1286, 6174±1587 and 5160±1324 
µm2 for type 1, 2A and 2X respectively (Staron et al., 2000). In concordance with Simoneau 
& Bouchard (1989), the aforementioned studies report substantial interindividual variability in 
fiber type composition and CSA. Regarding myogenic precursor cells, analysis of 3,507 
muscle fibers sampled from m. vastus lateralis in five healthy volunteers found no significant 
difference between the satellite cell population associated with type 1 fibers (0.067±0.01) and 
that observed in type 2 fibers (0.063±0.01) (Kadi, Charifi, & Henriksson, 2006).   
2.2.8 Assessment of skeletal muscle strength and endurance 
Exercise and recreational activities commonly rely on function in the lower extremities. 
Assessment of function in the knee extensors is common in studies on performance athletes, 
in pathological conditions, as well as in studies evaluating the effect of exercise interventions 
(McMaster, Gill, Cronin, & McGuigan, 2014; Park & Hopkins, 2013). Maximum strength is 
the maximum amount of force an individual can produce against an external load at a given 
time and can be evaluated trough different types of contraction (McMaster et al., 2014). A 
strong correlation between isometric and dynamic strength when tested with similar 
movements is reported in both athletes and recreationally trained men (McGuigan, Newton, 
Winchester, & Nelson, 2010; McGuigan & Winchester, 2008). Isometric testing is less 
available than 1 RM testing as it requires a force transducer and strain gauge, but is less 
vulnerable to confounding due to no change in joint angle and has been deemed highly 
reliable (McGuigan et al., 2010; McMaster et al., 2014). Estimating muscle strength by 
maximal voluntary contraction (MVC) relies on the test subject’s ability to activate motor 
units. Evidence suggests that maximal voluntary activation is just slightly inferior to the true 
maximum evoked by supramaximal artificial stimulation of the nerve trunk or intramuscular 
nerve (Shield & Zhou, 2004). When measuring muscle strength by volition, familiarization of 
test subjects is important in order to eliminate false low values. Valid recordings of isometric 
MVCs should display a force plateau along with repeated attempts of low variability. 
Furthermore, standardized verbal cheering is advocated and test subjects should be given the 
opportunity to reject MVCs they do not consider as maximal attempts (Gandevia, 2001; 
Shield & Zhou, 2004; Wilson & Murphy, 1996). 
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Measures of maximum isometric strength allow us to explore peak force, mean force and 
explosive force production. Rate of force development (RFD) quantifies the “slope of the 
force time curve” (Wilson & Murphy, 1996 p. 20), and is a common measure of explosive 
strength. The RFD parameter may have an impact on function in activities requiring fast and 
forceful contractions, and an increase in RFD in m. quadriceps femoris has been observed 
after a period of progressive, heavy resistance training (Aagaard, Simonsen, Andersen, 
Magnusson, & Dyhre-Poulsen, 2002) and fast-velocity concentric strength exercise (de 
Oliveira, Rizatto, & Denadai, 2013). Contradictory results are reported by Oliveira et al. 
(2013), who detected no change in early or late RFD following isometric strength training. 
Mirkov et al. (2004) observed good reliability in repeated tests of RFD of elbow flexors 
(ICC= 0.81) and elbow extensors (ICC=0.87). However, evaluation of reproducibility of 
lower limb RFD by coefficient of variation indicates that measures of RFD are prone to 
relatively high method errors. In order to attain valid RFDs, familiarization and repeated 
attempts are recommended (reviewed in: Wilson & Murphy, 1996).  
Muscular endurance or fatigue has no universal definition, but may describe the ability of 
skeletal muscles to perform repeated contractions against a sub-maximal load (Gandevia, 
2001). There is no standardized method of assessment although different protocols have been 
used to evaluate muscle endurance (De Ruiter, Mallee, Leloup, & De, 2014; Sahin, Ozcan, 
Baskent, Karan, & Kasikcioglu, 2011). Muscle fatigue is believed to originate from both 
central and peripheral factors, with a common understanding that mechanisms of fatigue are 
essentially related to processes at the peripheral level (Allen, Lamb, & Westerblad, 2008). 
Central fatigue pertains to a reduction in the supraspinal stimulation of motoneurons, and can 
be influenced by a subject’s ability to cope with exhaustion. As muscle fatigue arises, muscle 
receptors are subjected to a change in intracellular milieu. This may induce a shift in afferent 
signaling and a consequential reduced central drive of motoneurons (Gandevia, 2001; 
Westerblad & Allen, 2002). Release of Ca2+ by the sarcoplasmatic reticulum (SR) is pivotal in 
generating muscle contractions, and a reduction in Ca2+ concentration is considered an 
essential cause of peripheral muscle fatigue. Repeated muscle contractions against a sub-
maximal load causes a gradual shift from aerobic energy consumption to anaerobic energy 
consumption. The result is a reduced pH-level due to accumulation of lactic acid. Often 
perceived as a substantial contributor to muscle fatigue, acidosis has limited effect on muscle 
contractions and probably plays a role in muscle fatigue by triggering central factors. 
Anaerobic energy consumption also involves cleavage of creatine phosphate to creatine and 
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inorganic phosphate (Pi). The latter compound reduces the myofibrillar responsiveness to Ca
2+ 
as well as SR-release of Ca2+, thus having a direct effect on muscle fatigue at the tissue level 
(Allen et al., 2008; Westerblad & Allen, 2002). Muscle fatigue is also influenced by the 
accelerated production of ROS caused by muscle activity. ROS scavengers are reported to 
reduce the rate of muscle fatigue, while increased levels of ROS are believed to negatively 
affect SR release of Ca2+ and Ca2+ sensitivity (Allen et al., 2008).  
In a clinical setting, muscle fatigue arises along with an excessive feeling of discomfort and/or 
an inability to continue with the task given. Tests of muscle endurance explore the interplay 
of the required force, the maximum strength of the muscle(s) involved as well as fiber type 
distribution and metabolic capacity of the muscle cells (Allen et al., 2008).  
2.3 Summary  
SpA designates a group of inflammatory, rheumatic diseases characterized by axial and 
peripheral arthritis. Extra-articular manifestations are common, and patients report 
considerable relief of pain and stiffness following PA. The effect of chronic, systemic 
inflammation on muscle tissue is largely unknown. Studies evaluating muscle strength and 
body composition in SpA patients present conflicting results and the few reports examining 
muscle morphology are dated. As outlined in chapter 1 and 3 and in the research article, we 
sought to assess body composition, muscle strength and cellular variables in muscle tissue in 
SpA patients. We used immunohistochemical (IHC) assays to examine muscle fiber type 
distribution and muscle fiber CSA as well as number of myonuclei, satellite cells and 
leukocytes. The existence and amounts of proteins that determine muscle fiber size (chapter 
2.2.3) as well as regulators of muscle fiber function (chapter 2.2.5) have not been investigated 
in the present study. In an attempt to gain more thorough insight regarding muscle tissue in 
SpA, we plan to further explore the collected muscle biopsies by western blot (immunoblot), 
an analysis that uses antibodies to detect specific proteins (Paciello & Papparella, 2009).  
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3. Material and method 
3.1 Study sample 
(See article for information on study inclusion and patient-control matching.) 
Table 3. Inclusion and exclusion criteria for study participants with SpA 
Inclusion criteria Exclusion criteria 
Age 30-45 years Arthritis to the hip or knee joint or lower extremity 
injury within the last 12 months 
 
Male gender Myopathies 
BMI 18.5-30 Cognitive impairment 
SpA diagnosed by rheumatologist according to 
ASAS diagnostic criteria 
 
Per-oral corticosteroid treatment 
SpA symptoms ≥5 years 
 
 
Signed consent to participate  
Speaks Norwegian or English  
 
Recruited study participants had been diagnosed with SpA according to the ASAS 
classification criteria by a rheumatologist. Since there are no specific laboratory tests for SpA, 
the ASAS classification criteria can be used to classify SpA and are used for diagnostic 
purposes (Ehrenfeld, 2012; Rudwaleit et al., 2009). 
Table 4. ASAS classification criteria (http://www.asas-group.org/education/ASAS-
handbook.pdf) 
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Study participation was limited to the male gender. One reason is even though the prevalence 
gender difference is less than what was reported in earlier studies, the ratio still favors men 
(Lee et al., 2008). Several studies have shown less radiographic severity in female AS patients 
and a reported delay in diagnosis compared to male patients. It has also been reported that 
female AS patients have a higher prevalence of peripheral arthritis (Lee et al., 2008). If we 
had included female participants in this study, the additional age-range inclusion criteria 
would have left us addressing fertile women with SpA. The plausible use of oral 
contraceptives as well as physiological fluctuations in hormone levels due to menstrual cycles 
or pregnancy could pose as possible confounders to the dependent variables in this study 
(Oosthuyse & Bosch, 2010; Spangenburg, Geiger, Leinwand, & Lowe, 2012).  Additionally, 
disease activity may change during pregnancy; from no change in symptoms to a marked 
improvement or a flare of disease activity (Lee et al., 2008), possibly accounting for some of 
the observed fluctuation in disease activity in female SpA patients of fertile age. By 
constricting our inclusion criteria to male patients with SpA, we hoped to reduce the influence 
of confounders and provide a more homogenous study sample. On the other hand, this 
weakens the external validity, as one cannot generalize results to apply for both genders based 
on studies where participation is limited to the male sex (Short, Yang, & Jenkins, 2013; 
Sørbye, 1996).  
The desired age range of study participants was set to 30-45 years. In about 80% of the SpA 
patients the first symptoms present at an age younger than 30, and fewer than 5% of patients 
develop symptoms at older than 45 years (Braun & Sieper, 2007). Lower bound was set to 30 
years in the hopes that this would increase the chance of including patients who have had SpA 
for some time. Adults are reported to lose only 5-10% of muscle mass up to 50 years of age, 
but show a marked decrease in muscle mass from age 50-80 (Hunter, McCarthy, & Bamman, 
2004). The effect of age on skeletal muscle mass was explored in a study where MRI was 
employed to establish reference data for total and regional muscle mass in a large sample of 
men and women. Age was negatively correlated to muscle mass in the 45+ years age 
category, contrasting the non-relationship observed in the 18-44 years age category (Janssen 
et al., 2000). To reduce the chance of confounding results due to age-related changes like 
sarcopenia and loss of strength, the upper bound for age was set to 45 years in this study. 
Furthermore, since earlier recommendations on exercise in SpA focused on flexibility training 
(Dagfinrud et al., 2011), older SpA patients may have a history of less vigorous PA compared 
to healthy peers.  
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Control participants were recruited from hospital staff, friends or relatives of included patient 
participants as well as other acquaintances. Study inclusion and data collection was completed 
within the period primo September to ultimo November 2014.  
3.2 Outcome measures 
 
All participants completed questionnaires (att. 4 and 5) regarding age, level of education, 
occupational status and smoking behavior. In addition, habitual level of endurance- and 
strength exercise was self-assessed on a four-graded ordinal scale. 
3.2.1 Disease-specific characteristics 
All SpA participants completed the Bath Ankylosing Spondylitis Disease Activity Index 
(BASDAI) and Bath Ankylosing Spondylitis Functional Index (BASFI) questionnaires (att. 
4). BASDAI is an ASAS-endorsed, six-item, self-administered questionnaire. It is designed to 
measure patient-reported fatigue, back pain, peripheral joint pain, localized tenderness and 
morning stiffness on a scale ranging from 0 to 10. The sum of questions 1-4 is added to the 
average of questions 5 and 6. The total is then divided by 5 to give an average out of 10, with 
a BASDAI score of 4 or more often interpreted as active disease (Zochling, 2011). BASDAI 
is a convenient clinical tool with a mean time to complete of 67 sec and a test-retest reliability 
of r=0.93 (p<0.001) (Garrett et al., 1994). BASFI, a 10-item patient-generated index, was 
developed to monitor functional ability in AS patients. Eight questions concern self-assessed 
physical function, with the remaining two relating to the patient’s capacity to cope with 
activities of daily life (Calin et al., 1994). BASFI has a low respondent burden taking less than 
three minutes to complete, and is recommended by ASAS to evaluate disease impact and for 
use in clinical trials (Zochling, 2011). Test-retest reliability within 24 hours is reported to  
r=0.89 (p<0.001) (Calin et al., 1994), although a low median score may suggest a floor effect 
(Ruof, Sangha, & Stucki, 1999). 
Patient mobility was assessed by means of Bath Ankylosing Spondylitis Metrology Index 
(BASMI) (att. 6). This index was generated to provide clinicians with objective measures of 
primarily axial mobility in AS patients. Measures of cervical rotation, intermalleolar distance, 
tragus-to-wall distance, lumbar lateral flexion and lumbar flexion (modified Schobers) was 
graded on a 3-point scale from 0 to 2 in the first version of BASMI (Jenkinson et al., 1994). 
BASMI was later refined to a scale ranging from 0 to 10 (Jones et al., 1995), with the 11-point 
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version being more sensitive to change in disease activity (van der Heijde et al., 2012). Time 
to complete is estimated to 5 to 10 minutes, making it feasible in a clinical setting. It is also 
proposed by ASAS as the metrology index of choice in clinical trials. Interobserver reliability 
for the five metrology items is reported to range from r=0.94 (p<0.001) to r=0.99 (p<0.001) 
with similar high values for intrarater reliability (Zochling, 2011). 
3.2.2 Muscle morphology 
Muscle morphology was explored through muscle biopsy of the anterior thigh muscle. A 
competent researcher (professor Truls Raastad) with years of experience in biopsy sampling 
performed the biopsies.   
Recurrent exercise induces progressive cellular remodeling in response to increased metabolic 
demands. In addition to physiological adaptation following repeated training, single bouts of 
exercise can lead to perturbations at the molecular level. For instance, muscle contractions can 
increase cellular levels of ROS, and resistance training is associated with alterations in 
cellular anabolic and catabolic pathways post-exercise (Egan & Zierath, 2013; Murton & 
Greenhaff, 2013). In order to eliminate potential acute effects of exercise on study variables, 
participants were asked to refrain from exercise for 48 hours in advance of the muscle biopsy.  
Muscle tissue samples were obtained by use of the Bergström percutaneous needle technique 
(Dubowitz & Sewry, 2007; Mikell et al., 2013). The chosen site of biopsy was the midsection 
of m. vastus lateralis. With study participants in a supine position, the area around the biopsy 
site was draped and the skin and subcutaneous tissue was treated with local anesthesia 
(Xylocaine + adrenaline, 10 mg/ml +5 µg/ml; AstraZeneca, Södertälje, Sweden). A surgical 
blade was employed to make a 1-2 cm incision through the skin and muscle sheath. Antiseptic 
swabs were used to clean and apply pressure to the incision site until any bleeding stopped. A 
6 mm Pelomi needle (Albertslund, Denmark) with an assembled sliding cannula and closed 
cutting window was then inserted 2-3 cm along the muscle belly. The cannula window was 
then opened and suction was applied, causing the muscle to bulge into the open cutting 
window. In concert with manual suction, muscle tissue was then obtained by twice closing the 
cutting window. The procedure entails a feeling of deep pressure within the muscle belly as 
well as a twitching sensation when the sample is cut (Dubowitz & Sewry, 2007; Meola et al., 
2012). Upon completion of the biopsy, the skin edges were closed by three strips and dressed 
with an adhesive plaster. A compression bandage was applied to reduce the intramuscular 
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haematoma. Participants received information on wound care (att. 7), and a follow-up 
telephone call was made the next day to address any questions and potential complications. 
 
Figure 1. Muscle biopsy 
Tissue sampling, immunohistochemical analysis and image analysis 
(See article)  
Microscope 
A light source (EXFO, X1120PC-Q, Canada) connected to a light microscope (Olympus 
BX61, Tokyo, Japan) was used to quantify the stained biopsy sections. Pictures of marked 
dissections were taken by a digital camera (Olympus DP72, Tokyo, Japan) linked to the light 
microscope and analyzed by Cell-F software (Olympus, Tokyo Japan) for Windows XP 
(Microsoft, USA).  
3.2.3 Muscle function 
(See article for complementary information on testing procedure). 
Muscle function of QF was evaluated as maximal strength by means of isometric knee 
extension. The maximal number of repetitions sustained with a submaximal load assessed 
muscle endurance capacity.  
Prior to testing of maximal voluntary contraction (MVC), all participants performed five min 
of warm-up on a stationary bicycle at 100 watt and 60 rpm (Monark 839 Ergomedic, Vansbro, 
Sweden).  
42 
 
             
Figure 2. MVC test 
Test conductor was aware of group membership of the subjects being tested. In an attempt to 
reduce possible bias, every study participant was vocally encouraged to exert maximal effort. 
Furthermore, a similar phrase was used for each attempt at MVC (e.g. “1-2-3 – Give it your 
all! – hold – hold – hold – relax”. 
Table 5. Examined variables of muscle function in mm. quadriceps femoris 
Variables Right leg Left leg 
Maximal isometric force (Nm)   
Rate of force development (RFD)   
Number of repetitions at 30% of MVC   
Total workload (number of repetitions x kg)   
 
3.2.4 Body composition and muscle mass 
DXA 
DXA (Lunar iDXA, GE Healthcare, Buckinghamshire, United Kingdom) was used to 
measure body composition. Entering the clinical scene about 30 years ago, the DXA was 
primarily designed to asses bone mineral density (BMD) in bone disease like osteoporosis. 
However, transmission of X-rays through the body at high and low energies allows the DXA 
to measure not only BMD, but also total body and regional distribution of LBM and FM 
(Andreoli et al., 2009). Modern DXA software allows for separate measures of FM into 
gynoid and android FM. A study evaluating the reliability of the Lunar iDXA observed a 
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coefficient of variation of less than 1% for all body composition measures except for android 
fat with a precision error of 2.32% (Hind, Oldroyd, & Truscott, 2011). Measurement errors 
may be due to technical errors in measurement or biological variation like hydration status. 
Exercise and intake of food and fluid can lead to small measurement changes for values of 
body composition (Nana, Slater, Hopkins, & Burke, 2012, 2013). Consequently, we advised 
the study participants to fast for a minimum of four hours and refrain from exercise for 48 
hours leading up to the DXA scan.  
Prior to the DXA scan, participants were asked to undress to their underwear and t-shirt, and 
height and weight was recorded on a stadiometer (Seca 217, Seca gmbh & co. kg., Hamburg, 
Germany). Next, study participants lay supine on the DXA scanning table with the ankles and 
knees held together by ankle- and knee support bands. Arms were held to the side with palms 
turned towards the hips and thumbs facing upward. Participants were asked to lay still for the 
approximately 10 minutes duration scan. We used the total body scan mode determined by the 
manufacturer and all scans were analyzed using enCORE Software, Version 14.10.022 (GE 
Healthcare, Buckinghamshire, United Kingdom). Two separate operators performed scans 
and analyses. 
                
Figure 3. DXA scan 
MRI 
In addition to computed tomography (CT), the MRI is non-invasive and considered the gold 
standard in assessing regional body composition, with MRI having the advantage that it does 
not involve exposure to radiation (Andreoli et al., 2009; Tothill & Stewart, 2002). The MRI 
provides us with photographic slices of the region of interest that we can further analyze for 
CSA and volume of thigh muscles (see chapter 1.3.2) (Mijnarends et al., 2013; Tothill & 
Stewart, 2002).  
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All participants underwent magnetic resonance imaging (MRI) (Avanto TIM 76x18, Siemens, 
Erlangen, Germany) of the thigh at a private radiology center (Curato Røntgen, Oslo, 
Norway). Muscle CSA can vary throughout the muscle belly, and multiple measurements 
throughout the length of the muscle are advocated to achieve valid records of CSA (Raastad et 
al., 2010). The individual length of the femur bone was recorded as the mean of two attempts. 
This value was further applied to calculate the gap distance between the fifteen images 
obtained by a standardized MRI protocol (see article for scanning protocol).  
Images were produced by Siemens software (WB19, Siemens, Erlangen, Germany) and 
analyzed using OsiriX imaging software (Pixmeo, Geneva, Switzerland). Image nr. 1 was 
excluded on all participants due to difficulty in identifying the various muscle bellies at the 
level of the lower pelvis. Image nr. 14 and 15 were also excluded from analyses as they were 
taken at the level of the upper epicondyles and tibiofemoral joint, and failed to depict QF 
tissue. The muscle bellies of vastus medialis, vastus intermedius, vastus lateralis and rectus 
femoris were outlined in the anterior compartment on the remaining 12 images, and used to 
estimate total volume of QF as well as maximum and mean CSA. M. sartorius was 
indistinguishable to the belly of QF on a proportion of the upper images. Consequently, we 
decided to include CSA of m. sartorius on image 2 and 3 for all participants. When in doubt, 
an anatomical atlas was consulted (Sobotta atlas of human anatomy, 2006). Regarding control 
participant nr. 5, image nr. 2 did not present measurable muscle tissue, and CSA for this 
image was extrapolated from image 3 using the mean image 2/image 3 ratio from the 
remaining study participants. As to control participant nr. 9, images were compressed around 
the mid-section of the femur and lacked images of muscle tissue surrounding the proximal 
and distal femur. To account for this shortfall, two separate images from the midportion of the 
femur were excluded from CSA analysis. Image nr. 2 and 13 were extrapolated from 
neighboring images using the mean ratio from the other study participants.  
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Figure 4. Magnetic resonance images of the right and left thigh with the muscle bellies of QF 
outlined. Muscle presents as dark tissue, adipose tissue is light.  
 
3.3 Ethical considerations 
Concealing private information in the data collected was attained by limiting data access to 
the master student and supervisors, and by storing the records in a secure database.  
3.3.1 Potential risks and benefits for individual participants 
Participants were provided with information of potential risks and discomfort prior to giving 
written consent (att. 2 and 3). We assessed the potential risks of participating in the study to 
be low and transient. Physical risks were minimized by carefully following measurement 
protocols and by assuring that individuals involved in research procedures were well trained. 
However, some study participants experienced tenderness during and after the muscle biopsy 
as well as concurrent or delayed muscle soreness associated with testing of muscle function. 
The DXA and MRI required that the participant lay still for 10-15 minutes and evoked 
discomfort in some of the SpA patients who often experience axial stiffness when immobile.  
Participants did not receive monetary compensation, but were thoroughly informed of the 
results of their individual tests upon completion of the study.  
3.4 Methodological considerations 
Planning and completing a clinical study for the first time is a remarkably educational 
process. Certain methodological choices were made in advance of study outset based on 
presumptive obstacles. In retrospect, additional adjustments may have improved the quality of 
the study. 
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3.4.1 Research design  
The study design is a small cross-sectional study. An observational research design allows us 
to observe patients from a usual clinical practice and possibly emphasize certain 
characteristics in those affected by disease (Grimes & Schulz, 2002c). If the results of this 
study favor the alternative hypothesis, we may infer a possible association between the 
presence of SpA and muscle morphology, muscle function or appendicular lean mass. 
However, cross-sectional studies examine outcome and exposure at the same time, rendering 
it incorrect to translate an observed temporal association into a causal relationship (Grimes & 
Schulz, 2002a). 
The choice of study design allowed a sub-group of patients with SpA to be examined at one 
point in time in terms of muscle morphology, muscle function and muscle mass. Patients with 
an inflammatory, rheumatic disease often fluctuate in terms of disease activity and self-
reported pain and stiffness. In this study, repeated tests of dependent variables would have 
enhanced the validity and reliability of the tests. Additionally, extending the time course of 
tests may have allowed for the inclusion of natural fluctuations, thus providing more precise 
estimates of the dependent variables (Laake, Olsen, & Benestad, 2008). Repeated tests would 
however require a higher degree of motivation and co-operation from study participants as 
well as increased time- and financial resources.  
We did not define one main variable that we wished to explore and did not estimate the 
number of study participants by systematic sample size calculation. The aim of this study was 
to provide insight into a somewhat unexplored subject, and possibly observe tendencies that 
may further be tested with larger study samples or a different study design. Sample size was 
determined based on experience from other studies with similar outcome measures as well as 
assuring feasibility within the scope of a master thesis. Small studies are often deemed to lack 
statistical power (Whitley & Ball, 2002), and the modest number of participants in our study 
(n=20) may have inflated the risk of type 2 errors.  
3.4.2 Bias and confounding 
Those who opt to participate in clinical research have a tendency to be healthier than non-
volunteers, thereby potentially reducing the external validity of the study (Grimes & Schulz, 
2002b). Upon completing this study, we are left with the impression of higher levels of 
physical activity amongst the enrolled participants compared to the general population. 
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Additionally, the patients included had low to moderate disease activity as reported by 
BASDAI. Patients receiving anti-TNF medication had normal serological inflammatory 
markers, although they reported previous cycles of high disease activity. A clinical trial with 
an aim of observing potential differences in training response between SpA patients and 
controls could perhaps recruit a study sample that is more representative to the general SpA 
population.  
In addition to recruiting patients and controls within the same age group, we made an effort to 
match pairwise by means of BMI and level of physical activity. BMI is a tool that is often 
used in epidemiological research to observe the association between adiposity and risk of 
disease (Flegal, Kit, Orpana, & Graubard, 2013). However, BMI cannot discriminate between 
LBM and FM. Metabolically healthy people with enhanced muscle mass can be misclassified 
as overweight when using BMI. In parallel, individuals with low LBM and an increased FM 
can have normal BMI (Oliveros, Somers, Sochor, Goel, & Lopez-Jimenez, 2014). 
Consequently, we aimed at matching patients and controls on self-reported level of physical 
activity. Subjective measures of physical activity can however be influenced by different 
interpretations and recall bias. They are not regarded as entirely valid when compared to 
objective measures such as the criterion method doubly-labeled water (Vanhees et al., 2005; 
Westerterp, 2009). Although level of physical activity and physical fitness are closely related, 
physiological adaptations to exercise can vary among individuals (Blair, Cheng, & Holder, 
2001; Bouchard & Rankinen, 2001; Petrella et al., 2008). Thus, despite pairwise matching by 
self-reported amount of endurance- and resistance training, considerable differences between 
patients and controls in regards to physical fitness may have gone unspoken.  
All patients were currently on various NSAIDs or TNF-blockers. As discussed in chapter 
2.2.6, the effect of assorted medications commonly used in SpA on body composition and 
muscle tissue is unknown, and we cannot discard the possibility that pharmaceuticals may 
have influenced the outcome variables. We did not assess food intake among the study 
participants. Diets high in protein can have a positive effect on body mass and body 
composition (Westerterp-Plantenga, 2003) and we cannot dismiss a possible confounding 
effect of divergent food intake. Even though study participants were similar in regards to 
working full-time, we did not account for type of employment, nor for recreational activities 
spare endurance- and strength training. The amount of time spent on activities of daily living 
48 
 
at low and moderate intensities can affect total energy expenditure (Westerterp & Plasqui, 
2004), and we cannot preclude the impact of work and lifestyle on body composition.  
The laboratory technician who analyzed the biopsies and the operator who analyzed the DXA 
scans were aware of group membership, but not familiar with the disease in question. 
Accordingly, they were probably unsuspecting as to what tendencies to be alert to. Measures 
of muscle function and all statistical analyzes were performed by the master student who was 
aware of group membership and insightful regarding SpA disease. Although attempts were 
made to standardize all measurements, it is conceivable that knowledge of group membership 
may have influenced the outcome variables. 
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Article 
TITLE: Reduced appendicular lean body mass, muscle strength and size of 
type 2 muscle fibers in spondyloarthritis vs. healthy controls: A cross-sectional 
study. 
AUTHORS: Kristine R. Nordén, Hanne S. Dagfinrud, Amund Løvstad, and 
Truls Raastad 
ABSTRACT 
Objective: The effect of chronic, systemic inflammation on muscle tissue is largely unknown. 
The purpose of this study was to investigate body composition, muscle function and muscle 
morphology in patients with spondyloarthritis (SpA).  
Methods: Ten male SpA patients (mean ±SD age 39 ±4.1 years) were compared with ten 
healthy controls matched for age, body mass index and self-reported level of exercise. Body 
composition was measured by dual energy X-ray absorptiometry. Quadriceps femoris (QF) 
strength was assessed by maximal isometric contractions prior to test of muscular endurance. 
Magnetic resonance imaging of QF was used to calculate specific muscle strength. 
Percutaneous needle biopsy samples were taken from m. vastus lateralis.  
Results: SpA patients presented with significantly lower appendicular lean body mass (LBM) 
(p= 0.02), but there was no difference in bone mineral density, fat mass or total LBM. 
Absolute and specific strength of the left QF was significantly lower in SpA patients (p= 0.01 
and 0.04) with a parallel trend observed for the right leg. Biopsy samples from the SpA 
patients revealed significantly smaller cross-sectional area (CSA) of type 2 muscle fibers (p= 
0.04), but no difference in CSA type 1 fibers.   
Conclusion: Results indicate that the presence of SpA disease is associated with reduced 
appendicular LBM, muscle strength and type 2 fiber CSA. Further research is needed to 
investigate whether catabolic pathways are up-regulated in SpA patients. Strength training 
may be an effective countermeasure against these negative effects on muscle indicated in SpA 
patients. 
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INTRODUCTION 
The term spondyloarthritis (SpA) constitutes a group of related inflammatory, rheumatic 
diseases with Ankylosing Spondylitis (AS) often viewed as the most severe subtype. 
Hallmark clinical features are inflammatory back pain, peripheral arthritis and enthesopathy 
along with extra-articular manifestations such as uveitis, psoriasis and inflammatory bowel 
disease (1, 2), and an increased risk of cardiovascular disease (3, 4). Depending on the prime 
disease manifestations, patients are subgrouped into axial SpA for those presenting with a 
predominant involvement of the spine or sacroiliac joints or peripheral SpA (5, 6).  
In addition to optimal pharmaceutical treatment, supervised and individually tailored exercise 
is advocated as the essential treatment for SpA (7). Furthermore, recent studies on SpA 
patients indicate that high-intensity endurance exercise can ameliorate traditional 
cardiovascular risk factors without causing a flare-up in disease activity (8, 9). For optimal 
health effects, a combination of both endurance and strength exercise is advocated for the 
general population (10). However, a systematic review on exercise interventions in SpA 
identified a lack of clinical trials with muscle strength training protocols that adhere to the 
American College of Sport Medicine recommendations (11).  
Studies have demonstrated a possible negative effect of inflammatory processes on muscle 
tissue (12-14). SpA patients often describe beneficial effects of physical activity (PA) on pain 
and stiffness (15), indicating a possible direct involvement of muscle tissue in SpA (16). 
Lower muscle strength in SpA patients compared to healthy controls is reported (17-19), 
although normal level of muscle force is also described (20). Regarding body composition, 
reduced lean body mass (LBM) and/or shifts in fat mass (FM) are observed in SpA patients 
compared to controls in a few cross-sectional studies (19, 21, 22), but discordant results have 
also been published (23-26). At the level of local muscle tissue, dated studies observed mild 
to moderate histological abnormalities in AS patients (16, 27, 28). To our knowledge, there is 
a lack of novel studies examining muscle morphology in SpA. Likewise, there is a paucity of 
studies simultaneously addressing body composition, local muscle mass and muscle strength 
in this patient population. In addition to variables pertaining to body composition and muscle 
force, we aimed to utilize immunohistochemical analysis (29) to assess muscle fiber type 
distribution, myofiber size and myonucelar domain as well as number of satellite cells and 
leukocytes. Thus, the purpose of this exploratory cross-sectional study was to test the 
hypothesis that the presence of SpA disease may be associated with reduced LBM and/or 
muscle strength. We further hypothesized that muscle biopsies yielded from SpA patients 
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display manifestations of inflammatory disease and abnormal muscle morphology in 
comparison to healthy controls.  
MATERIALS AND METHOD 
Participants 
A sample of 10 male patients with axial SpA according to the Assessment of 
SpondyloArthritis international Society (ASAS) classification criteria (30) were recruited 
from the out-patient clinic from the Rheumatology unit at Diakonhjemmet hospital, Oslo and 
from patient organizations. Additional inclusion criteria were SpA symptom duration ≥5 
years, age 30-45 years and body mass index (BMI) (kg/m2) 18.5-30. Arthritis to the hip or 
knee joint or injury to the lower extremity in the past 12 months were considered exclusion 
criteria in addition to neuromuscular disease, cognitive impairment and a current or previous 
history of per-oral corticosteroid treatment. A convenient sample of 10 healthy controls fitting 
the same relevant inclusion criteria were enrolled in the study and pairwise matched to the 
patients by BMI and self-reported level of endurance-and strength training. The study was 
approved by the Regional Ethics Committee and all procedures were performed according to 
the Helsinki declaration (31). Participants were provided with oral and written information 
concerning the study and signed a written consent form before enrolling in the study.  
Subject characteristics 
All participants completed a questionnaire regarding age, level of education, occupational 
status and smoking behavior. In addition, habitual level of endurance- and strength exercise 
was self-assessed on a four-graded ordinal scale and preferred type of exercise was registered 
by verbal interview. Regarding SpA participants, Human Leukocyte Antigen (HLA) B27 
phenotype, disease symptom duration and time of diagnosis was collected from the patients. 
Disease activity was evaluated by serum blood samples analyzed for C-reactive protein (CRP) 
and Eryhtrocyte sedimentation rate (ESR) (32). In addition, Bath Ankylosing Spondylitis 
Disease Activity Index (BASDAI), a self-reported questionnaire, was used as a measure of  
subjective disease activity (33). Physical burden of disease was self-assessed by the Bath 
Ankylosing Spondylitis Functional Index (BASFI) (34). Axial mobility was recorded by an 
experienced physical therapist (KRN) using the 11-step Bath Ankylosing Spondylitis 
Metrology Index (BASMI) (35-37).  
Measurements 
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Body composition  
Measures of body height and weight were recorded on a stadiometer (seca 217, seca gmbh & 
co. kg., Hamburg, Germany) and used to calculate BMI. Dual energy X-ray absorptiometry 
(DXA) (Lunar iDXA, GE Healthcare, Buckinghamshire, United Kingdom) and enCORE 
Software (Version 14.10.022, GE Lunar) was used to estimate total and regional distribution 
of LBM and FM, including dispersion of android and gynoid fat. Appendicular skeletal 
muscle mass (RSMI) was predicted by the Baumgartner-equation (38): RSMI= (tissue mass 
arms) + (tissue mass legs)/ (height[m])2. To reduce the possibility of measurement error due 
to biological variation in hydration status (39, 40), participants were asked to fast for a 
minimum of four hours and refrain from exercise for 48 hours leading up to the DXA-scan.  
Quadriceps femoris (QF) volume and cross-sectional area (CSA) 
All participants underwent magnetic resonance imaging (Avanto TIM 76x18, Siemens, 
Erlangen, Germany) of the thighs at a private radiology center (Curato Røntgen, Oslo, 
Norway). The scanning protocol consisted of three localizer scans for positioning, a T1-
weighted turbo spin echo (TSE) sequence (15 slices of 5 mm thickness (1/15-15/15 of femur 
length), repetition time (TR) 432 ms, echo time (TE) 9,2 ms, field of view (FOV) 450 x 
337,5 mm, voxel size 1x1x5 mm, TSE factor 5). Fifteen images were produced by Siemens 
software (WB19, Siemens, Erlangen, Germany) and analyzed by a viewing tool (OsiriX 
Imaging Software, Pixmeo, Geneva, Switzerland).  
Image nr. 1 was excluded on all participants due to difficulty in identifying the various muscle 
bellies at the level of the lower pelvis. Image nr. 14 and 15 were also excluded from analyses 
as they were taken at the level of the femur epicondyles and tibiofemoral joint, and failed to 
depict QF tissue. The perimeter of the muscle bellies in the anterior compartment of the thigh 
was manually outlined as region of interest (ROI) on the remaining twelve images. 
Interpolation at intervals of 1:15 femur length distance was used to estimate total volume of 
QF. Mean QF CSA was computed by averaging the volume of all twelve ROIs and maximum 
QF CSA was determined by identifying the largest ROI captured. 
Muscle function  
Succeeding a five-minute warm-up protocol on a stationary bicycle (Monark 839 Ergomedic, 
Vansbro, Sweden), maximal voluntary contraction (MVC) of the knee extensors was 
measured at 90º knee angle using an isometric knee-extension device (GYM 2000 AS, 
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Vikersund, Norway). Participants were stabilized in the apparatus with straps secured over the 
hips and shoulders and settings adjusted to ensure a 90º angle at the hip and knee joints. The 
lever arm of the knee-extension device with an attached force transducer (HBM U2AC2, 
Darmstadt, Germany) was individually adjusted so that the contact point with the participant’s 
calf was just proximal to the line of the medial malleolus. Participants began with three 
incremental bilateral isometric test contractions to familiarize with the testing procedure (41). 
Succeeding the warm-up protocol, the participants performed three unilateral maximal 
isometric contractions. Each contraction lasted for five sec, with 60 sec recovery time 
interspaced between each attempt. The right leg was tested first on all participants, followed 
by the left leg. Participants were instructed to attain maximal force as quickly as possible and 
MVC torque (Newton meter –Nm) and rate of force development (RFD) was recorded from 
the best trial. LabView software (National Instruments Corporation, Austin, TX, USA) was 
used for data acquisition and inspection of time-force curves. Specific muscle strength 
(maximal voluntary torque pr. unit muscle) was calculated as the MVC Nm/total QF volume 
ratio and MVC Nm/max QF CSA ratio. 
Following the MVC tests, the participants completed a test of muscular endurance. They were 
asked to perform as many repetitions of knee extension as possible with a resistance of 30% 
of MVC. Each repetition was performed at the pace of a metronome (Korg metronome MA-
30, China) with one second in the concentric phase and one second in the eccentric phase. 
Initiating the movement with 90 degrees of flexion in the knee, the knee was fully extended 
and then lowered back to the starting position. Fatigue was defined as the inability to fully 
extend the knee at the pace of the metronome for three consecutive repetitions. A hand tally 
counter (Clas Ohlson, Insjön, Sweden) registered the total number of repetitions. Total 
workload (number of repetitions x kg) was then recorded.  
Muscle morphology 
Biopsy handling 
In an attempt to eliminate the acute effects of exercise on study variables (42, 43), participants 
were asked to abstain from exercise for 48 hours prior to muscle tissue sampling. With 
participants in a supine position, the muscle biopsy was obtained under local anesthesia 
(Xylocaine + adrenaline, 10 mg/ml + 5 µg/ml; AstraZeneca, Södertälje, Sweden). A 
percutaneous biopsy was taken from the midsection of m. vastus lateralis using a 6 mm 
Pelomi needle (Albertslund, Denmark) with manual suction and a double-chop method. The 
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same person completed all muscle biopsies, and attempts were made to collect the samples 
from the same tissue depth. A total of approximately 100-150 mg tissue was obtained and 
further divided into specific pieces for immunohistochemistry (finest bundles, 30-40 mg) and 
homogenization (1-2 x 50 mg). Following excision, tissue samples were rinsed prior to being 
frozen in isopentane on dry ice and stored at -80ºC until further analysis. 
Immunohistochemical analysis: 
Tissue samples were thawed to -20ºC and serial 8-µm thick sections were cut using a 
microtome (CM 1860 UV, Leica Microsystems; Nussloch, Tyskland), and mounted on 
microscopic slides (Superfrost Plus, Thermo Scientifi, MA, USA). Muscle sections double 
stained (see appendix) for SC71/Dystrophin were blocked for 45 min with 1% BSA (bovin 
serum albumin; Cat#37525, Thermo SCIENTIFIC, USA), and Pax7/Laminin for 10 min with 
a protein-blocker (Cat#X090930-2, Protein Block, Serum Free, Ready–To–Use, Denmark) 
before incubation with appropriate primary antibodies (see appendix) diluted in blocking 
solution either overnight at 4 °C (SC71/dystrophin, CD68/dystrophin, CD66b/dystrophin) or 
60 min in room temperature (Pax7/Laminin). Monoclonal antibodies against Pax7 were used 
to visualize satellite cells, CD68 and CD66b to visualize leukocytes (macrophages and 
neutrophils respectively), SC71to visualize fiber type distribution (MHC II) and polyclonal 
antibodies against laminin and dystrophin to identify cellular position (Image 1 and 2).  
Slides were thereafter washed 3 x 10 min in 0.05 PBS- t solution and incubated for 45 min 
with an appropriate secondary antibody (see appendix), washed again 3 x 10 min in 0,05 PBS- 
t solution, coated with a coverslip and glued with ProLong Antifade Reagent with DAPI 
(Cat#P36935, molecular probes, Life Technologies, USA) and left to dry overnight at room 
temperature. A high- resolution camera (DP72, Olympus Corp., Tokyo Japan) mounted on a 
microscope (BX61, Olympus Corp., Japan) with a fluorescent light source (X-cite 120PCQ; 
EXFO Photonic Solutions Inc., Mississauga, ON, Canada) was used to visualize and take 
pictures of the muscle sections.  
Image analysis:  
The number of fibers and positive cells were manually counted by marking each fiber and 
positive cells on a blueprint (Black-white photos taken with 4x magnification) with a pen 
while simultaneously pressing a turnstile (Laboratory Counter). Muscle fibers cut 
longitudinally, fibers with fractured membranes and fibers with unclear staining were 
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excluded from further analysis. The counted muscle fibers were used to determine the number 
of satellite cells, CD68 and CD66b positive cells per muscle fiber and per fiber phenotype. 
The counting criterion for satellite cells was co-localization of Pax7 and DAPI staining within 
the laminin staining showed in image 1. Both intracellular and extracellular leukocytes 
(macrophages and neutrophils) were quantified by counting criterion of co-localization of 
DAPI staining and CD68 or CD66b, and whether the positive cells were located inside or 
outside dystrophin staining (Image 2A and B).   
                
Image 1. Pax7 positive cell (satellite cell) inside the yellow square. Red stain = laminin, green stain = Pax7 
= and blue stain = DAPI (nuclei) 
 
 
Image 2. A: CD66b positive cell (neutrophil granulocyte) inside the yellow square. Red stain = laminin, 
green stain = CD66b and blue stain = DAPI (nuclei). B: CD68 positive cell (macrophage) inside the yellow 
square. Red stain = laminin, green stain = CD68 and blue stain = DAPI (nuclei).  
Myonuclei were analyzed with ImageJ using Fiji image and Cell counter processing package 
(http://fiji.sc/Cell_Counter) (Image 3A). To achieve satisfactory statistical power, 50 muscle 
fibers of each fiber type were included in the analysis (44). DAPI staining with the geometric 
 
 
A B 
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center within the dystrophin stain was defined as myonuclei (Image 3B) (45). Myonuclei are 
presented as number per muscle fiber and myonuclear domain was calculated by dividing the 
number of myonuclei by muscle fiber CSA. 
 
Image 3. A: Counting myonuclei. Biopsy marked with dystrophin (red stain), MHC II (green stain) and 
DAPI (blue stain). Roman numerals indicate fiber type I and II. White numbers mark myonuclei in type I 
fibers and red numbers for type II fibers. B: Blue Stain = DAPI (myonuclei) and red markings = 
dystrophin. Myonuclei branded with M were determined to have its geometric center (nucleus center) 
inside the dystrophin labeling. 
TEMA (ChekVision, Hadsund, Danmak) was used to analyze the intensity of SC-71 staining 
for fiber type determination, and fiber CSA was analyzed by calculating the area within the 
dystrophin staining (Image 3).  
Statistical analyses 
Statistical analysis and tests were carried out using SPSS (version 21, IBM, Armonk NY, 
USA) and GraphPad Prism (version 6, GraphPad Software, La Jolla CA, USA). Descriptive 
statistics were calculated for each outcome variable and presented as mean with standard 
deviation and minimum and maximum values. Preliminary analysis checked for normality of 
all variables by visual inspection of histograms and the Shapiro-Wilk test. To analyze patient-
control differences, normally distributed variables were compared using paired samples t-test. 
Skewed variables were log-transformed prior to parametric tests or analyzed by Wilcoxon 
signed ranks test.  Ordinal variables were compared by Pearson chi square test. Significance 
was accepted at the 0.05-level for all statistical analyses. No systematic sample size 
calculation was performed by virtue of the pilot character of the study. 
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RESULTS 
Participant characteristics and disease activity 
Control participants were significantly taller and heavier than their patient fellow, although 
BMI was similar between groups (table 1). There was no difference between patients and 
controls in terms of age, employment status, smoking behavior or self-reported level of 
endurance- and strength exercise. Patients included in the study presented with a mean disease 
symptom duration of 15.5 ±6.6 years. Regarding diagnosis, six patients had AS, one had PsA, 
and the remaining three presented with axial SpA. One patient had previously undergone 
prosthetic replacement of the left hip due to congenital causes, and measures of muscle 
function and QF volume and CSA from his left leg were therefore excluded from all 
comparative analyses.  
Body composition 
There was no significant difference in bone mineral density (BMD) or BMD T-score between 
patients and their respective controls (Table 2). Regarding muscle mass, there was no 
difference in total LBM. Appendicular lean mass (RSMI) was however significantly lower in 
the patient group (p=0.02) (Table 2). Both groups displayed a wide range of FM, and there 
was no significant difference in total body fat %, android fat % or gynoid fat % (Table 2).  
QF volume and CSA 
Within-group paired samples correlations of total QF volume, mean and maximal CSA 
measures of the right and left leg was very strong and significant for both patients (range: r=  
0.92-0.97, n= 9, Pat 01 excluded) and controls (range: r= 0.98-0.99, n= 10) (see appendix). 
Total QF volume of the right and left leg was significantly higher in control participants 
(Table 3). Mean QF CSA right leg was similar between groups and the moderate difference in 
mean QF CSA left leg was also non-significant (Table 3). We observed a trend towards lower 
maximal QF CSA in the right leg (p=0.14) and left leg (p=0.06) in the patients (Table 3).  
Muscle function 
Statistical evaluation of within-group paired samples correlation presented a non-significant, 
moderate positive relationship between measures of RFD right and left leg for both patients 
(r= 0.45, n= 9, Pat 01 excluded) and controls (τ= 0.33) (see appendix). Regarding other 
variables of muscle function, correlation with data from the contralateral leg was very strong 
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for patients (range: r= 0.85-0.94, n= 10) and controls (range: r= 0.78-0.95) (see appendix). 
Between-group analyses of muscle function revealed no significant difference in RFD (Table 
3). The SpA patients had significantly lower values for MVC torque left leg (175 ±42 Nm, Pat 
01 omitted) compared to the controls (223 ±32 Nm, Ctr 01 omitted) (p= 0.01, CI:-80.9;-14.4), 
with a similar trend for the right leg (201 ±35 Nm vs. 227 ±26 Nm, p= 0.08, CI:-57.0;4.1) 
(Figure 1). There was no significant difference in measures of specific strength when force 
was normalized to total QF volume and maximal QF CSA on the right leg (Table 3). Muscle 
strength normalized to QF maximal CSA left leg was significantly lower in the SpA patients 
(p=0.04), with a complementary trend detected for muscle force normalized to total left QF 
volume (p=0.12) (Table 3). Regarding muscle endurance, the number of repetitions at 30% 
MVC was practically identical (Table 3). There was a significant group difference in total 
workload right leg and a corresponding trend for the left leg (Table 3).  
Muscle morphology 
Mean ±SD number of muscle fibers attained and measured was 578 ±211 and 536 ±183 for 
patients and controls respectively (p= 0.65, CI: -159.9;243.7).  
Fiber type distribution and fiber CSA 
Muscle fiber type distribution was similar between patients and controls, although the 
individual variation was large in both groups (Table 4). Mean type 1 fiber CSA was similar 
between patients (mean ±SD 5269 ±1890 µm2) and controls (5598 ±1355 µm2) (p= 0.54, CI: -
1502.3;884.3), whereas mean fiber CSA of type 2 fibers was 24.7% larger in controls (7019 
±1585 µm2) compared to patients (5474 ±1840 µm2) (p= 0.04, CI: -3281.0;-83.2) (Figure 2). 
Ratio of mean type 2 and type 1 fiber CSA was significantly higher in controls (Table 4). 
Myonuclei and satellite cells 
Mean number of myonuclei and central nuclei was comparable between groups (Table 4). 
There was no group difference in satellite cells pr. type 1 fibers, whereas the tending 
difference in satellite cells for type 2 fibers was non-significant (Table 4). Compared to 
controls, patients presented with a similar myonucelar domain for type 1 fibers (1469 ±240 
µm2 vs. 1478 ±189 µm2, p= 0.93, CI: -244.7;226.1), and a non-significant tendency for lower 
type 2 fiber myonucelar domain (1351 ±243 µm2 vs. 1512 ±239 µm2, p= 0.15, CI: -
392.6;70.2) (Figure 3). 
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CD66b and CD68 positive cells 
The amount of CD66b (marker for neutrophils) positive cells per 100 muscle fibers was 
similar (2.8 ± 2.1 and 1.7 ±0.9 for patients and controls respectively) and test of log-
transformed variables was non-significant (p= 0.51, CI:-0.65;1.21) (Figure 5). There was a 
tendency for increased level of CD68 (marker for macrophages) positive cells in patients 
(10.6 ±3.9 per 100 fibers) compared to controls (7.9±1.8), but the difference was non-
significant (p= 0.11, non-parametric test) (Figure 4).  
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TABLES 
Table 1. Subject characteristics* 
Variable Patients 
n=10 
Controls 
n=10 
P (95% CI 
lower; upper)^ 
Age (as of 31.12.14) 39 ±4.1 (33-44) 38 ±5.1 (31-45) 0.57(-3.7;6.3) 
Body height (cm) 178.1 ±6.4 (169.5-190.5) 181.8 ±6.3 (174.5-190.5) 0.04 (-7.3;-0.2) 
Femur length 42.4 ±2.4 (39.5-46.4) 45.4 ±2.4 (42.5-49.5) 0.002 (-4.7;-1.4) 
Femur length/Body height (%) 24 ±1 (23-25) 25 ±1 (23-27) 0.01 (-0.02;-
0.004) 
Body mass (kg) 75.2 ±7.8 (65.0-90.6) 79.9 ±11.4 (74.2-95.5) 0.04 (-9.0;-0.3) 
BMI, kg/m2 23.6 ±1.3 (21.9-25.6) 24.0 ±2.3 (20.0-27.8) 0.43 (-1.6;0.7) 
Smoking behavior 
Non-smoker, n (%) 
Previous smoker, n (%) 
Current smoker, n (%) 
 
8 (80) 
1 (10) 
1 (10) 
 
7 (70) 
3 (30) 
0 (0) 
0.35§ 
Full-time employment, n (%) 10 (100) 10 (100) 1.00 
Level of endurance exercise (1-4) 2.3 ±0.7 (1-3) 2.2 ±0.6 (1-3) 0.89§ 
Level of strength exercise (1-4) 1.8 ± 0.6 (1-3) 2.0 ±0.7 (1-3) 0.77§ 
Diagnosis    
AS, n (%) 6 (60)  - 
Axial SpA, n (%) 3 (30)  - 
PsA, n (%) 1 (10)  - 
HLA-B27 positive, n (%) 9 (90)  - 
Time since diagnosis, years 10.0 ±7.9 (1-28)  - 
Duration of symptoms, years 15.5 ± 6.6 (7-29)  - 
BASDAI score 2.7 ±1.1 (0-3.7)  - 
BASFI score 0.9 ±0.8 (0-2.6)  - 
BASMI score 2.3 ±1.1 (0.7-4.6)  - 
CRP 7.0 ±7.7 (<1-21)  - 
ESR 9.3 ±9.7 (<1-26)  - 
Anti-inflammatory medication    
NSAIDs, n (%) 6 (60) 0 (0) - 
DMARDs, n (%) 2 (20) 0 (0) - 
TNF-inhibitors, n (%) 4 (40) 0 (0) - 
*Values are mean ±SD (range) unless otherwise indicated. ^Comparison between patients and controls tested by 
paired samples t-test unless otherwise indicated. §: Pearson Chi Square test. AS: Ankylosing Spondylitis. 
BASDAI: Bath AS Disease Activity Index. BASFI: Bath AS Functional Index. BASMI: Bath AS Metrology 
Index. BMI: Body mass index. CI: Confidence Interval. CRP: C-reactive protein. DMARDs: Disease modifying 
anti-rheumatic drugs. ESR: Erythrocyte sedimentation rate. NSAIDS: Non-steroidal anti-inflammatory drugs. 
PsA: Psoriasis arthritis. SpA: Spondyloarthritis. TNF: Tumor Necrosis Factor.  
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Table 2. Body composition analysis* 
Variable Patients 
n=10 
Controls 
n=10 
P (95% CI lower; 
upper)^ 
BMD, g/cm2 1.27 ±0.04 (1.20-1.33) 1.31 ±0.13 (1.11-1.60) 0.39 (-0.15;0.06) 
BMD, T-score 0.65 ±0.43 (0-1.3) 1.09 ±1.33 (-0.9-4.0) 0.37 (-1.5;0.6) 
Lean body mass, kg/m2 18.2 ±1.8 (15.1-21.3) 18.6 ±1.6 (17.1-21.6) 0.32 (-1.2;0.4) 
Appendicular lean mass;  
RSMI, kg/m2 8.3 ±0.9 (7.2-9.6) 8.8 ±0.8 (8.0-10.1) 0.02 (-0.9;-0.1) 
Body fat, % 21.9 ±7.0 (8.4-30.2) 20.1 ±6.2 (12.6-31.2) 0.47 (-3.5;7.1) 
Android fat, % 25.3 ±10.9 (6.3-39.7) 21.6 ±10.1 (10.6-36.5) 0.31 (-4.1;11.3) 
Gynoid fat, % 21.0 ±6.9 (8.2-29.6) 20.8 ±5.7 (15.0-32.8) 0.95 (-5.3;5.6) 
*Values are mean ±SD (range) unless otherwise indicated. ^Comparison between groups tested by paired 
samples t-test unless otherwise indicated. §: Wilcoxon signed ranks test. BMD: Bone mineral density. CI: 
Confidence Interval. RSMI: Relative skeletal muscle index. 
Table 3. Quadriceps femoris – parameters of volume, CSA and muscle function*  
Variable Patients 
n=10(#:n=9) 
Controls 
n=10 (#: n=9) 
P (95% CI lower; 
upper)^ 
QF total volume    
Right leg, cm2 2093 ±361 
(1501-2676) 
2316 ±268  
(1879-2718) 0.01 (-386.7;-59.7) 
Left leg, cm2# 1977 ±415  
(1413-2708) 
2278 ±304 
(1793-2691) 0.01 (-489.2;-112.6) 
QF mean CSA     
Right leg, cm2 62 ±9 (48-76) 64 ±7 (53-72) 0.42 (-6.5;3.0) 
Left leg, cm2# 58 ±10 (45-74) 62 ±8 (51-72) 0.17 (-10.2;2.2) 
QF max CSA    
Right leg, cm2 84±10 (66-100) 88±9 (75-105) 0.14 (-9.7;1.6) 
Left leg, cm2# 79 ±12 (63-95) 86 ±10 (72-104) 0.06 (-14.3;0.3) 
Specific strength     
MVC Nm/QF total vol., 
right leg, Nm/cm3 
 
0.097 ±0.01 (0.08-0.12) 
 
0.098 ±0.01 (0.09-0.11) 0.79 (-0.01;0.01) 
MVC Nm/QF total vol., 
left leg, Nm/cm3# 
 
0.090 ±0.01 (0.07-0.11) 
 
0.098 ±0.01 (0.09-0.11) 0.12 (-0.02;0.00) 
MVC Nm/QF max CSA, 
right leg, Nm/cm2 
 
2.41 ±0.37 (1.92-3.04) 
 
2.60 ±0.25 (2.22-2.97) 0.20 (-0.50;0.12) 
MVC Nm/QF max CSA, 
left leg, Nm/cm2# 
 
2.22 ±0.37 (1.75-2.82) 
 
2.60 ±0.24 (2.26-2.99) 0.04 (-0.74;-0.02) 
RFD    
Right leg, Nm/10 ms 1716 ±447 (1095-2577) 1873 ±937 (769-3632) 0.95 (-0.44;0.42)£ 
Left leg, Nm/10 ms# 1621 ±314 (1274-2273) 1949 ±889 (1187-4194)  0.24 (-0.38;0.11)£ 
Muscle endurance                                                            
Number of repetitions, 
right leg 35.4 ±14.3 (15-53) 37.9 ±6.2 (29-50) 0.63 (-13.8;8.8) 
Number of repetitions, 
left leg# 40.0 ±13.4 (23-60) 39.1 ±10.4 (26-57) 0.89 (-13.5;15.3) 
Total workload 
(reps x kg), right leg, kg 
556.6 ±206.8  
(248.7-809.2) 
680.8 ±133.2  
(479.2-946.4) 0.05 (-246.7;-1.7) 
 Total workload 
(reps x kg), left leg, kg# 
563.7 ±217.0  
(287.0-946.1) 
685.8 ±177.4 
(427.6-1029.6) 0.14 (-295.1;51.0) 
*Values are mean ±SD (range) unless otherwise indicated. #: N= 9 patients, 9 controls. Excludes pair 1 due to 
prosthesis left hip Pat 01. ^: Comparison between groups tested by paired samples t-test unless otherwise 
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indicated. £: Log-transformed variable, paired samples t-test. CSA: Cross-sectional area. MVC: Maximal 
voluntary contraction. Nm: Newtonmeter. QF: Mm. quadriceps femoris. RFD: Rate of force development.  
Table 4. Muscle morphology – parameters obtained from biopsy of m. vastus lateralis* 
Variable Patients 
n=10 
Controls 
n=10 
P(95% CI lower; 
upper)^ 
Muscle fiber distribution    
Type 1, % 54.9 ±13.8 (33.6-76.8) 48.5 ±11.4 (30.5-68.3) 0.32 (-7.5;20.5) 
Type 2, % 45.1 ±13.8 (23.2-66.4) 51.5 ±11.4 (31.7-69.5) 0.34 (-4.2;10.8) 
Ratio CSA type 2/ type 1 1.05 ±0.17 (0.83-1.37) 1.27 ±0.22 (0.95-1.94) 0.05 (-0.442;-0.002) 
Myonuclei     
Type 1, pr. fiber 3.6 ±1.1 (2.2-6.0) 3.8 ±0.6 (3.1-4.8) 0.65 (-0.96;0.63) 
Type 2, pr. fiber 4.0 ±1.1 (2.6-6.0) 4.6 ±1.0 (3.2-6.5) 0.25 (-1.75;0.51) 
Central nuclei    
Type 1, pr. fiber 0.02 ±0.03 (0.00-0.10) 0.08 ±0.14 (0.00-0.44) 0.20§ 
Type 2, pr. fiber 0.03 ±0.03 (0.00-0.08) 0.08 ±0.11 (0.00-0.32) 0.26§ 
Satellite cells, Pax7-positive    
Type 1, pr. 100 fibres 8.8 ±8.0 (1.5-29.7) 6.4 ±4.2 (1.6-17.1) 0.62 (-0.61;0.97)£ 
Type 2, pr. 100 fibres 5.5 ±2.7 (2.6-11.3) 8.0 ±6.0 (3.4-24.3) 0.13 (-0.76:0.12)£ 
*Values are mean ±SD (range) unless otherwise indicated. §: Wilcoxon signed ranks test. £: Log-transformed 
variable, paired samples t-test. CD68: marker for macrophages. CD66b: marker for neutrophils. CSA: Cross-
sectional area. ECM: Extracellular matrix.  
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Figure 1. Maximal voluntary contraction (MVC) torque measured as isometric contraction of m. quadriceps 
femoris. Lines drawn signify the pairwise match of patient-control.  
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Figure 2. Muscle fiber CSA for type 1 and type 2 fibers. Lines drawn signify the pairwise match of patient-
control.  
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Figure 3. Myonuclear domain for muscle fiber type 1 and type 2. Lines drawn signify the pairwise match of 
patient-control.  
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Figure 4. Number of CD68 positive macrophages and CD66b positive neutrophils in ECM. Lines drawn signify the 
pairwise match of patient-control – some lines appear duplicated as they represent pairs with similar values.  
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DISCUSSION 
The main findings of the present study were a significant lower appendicular LBM and 
muscle fiber type 2 CSA, as well as a tendency towards inferior muscle strength in SpA 
patients compared to healthy controls. Furthermore, in the muscle biopsies of SpA patients, 
we detected a moderate trend towards increased frequency of macrophages, heterogeneous 
leukocytes that can both stimulate and attenuate muscle tissue repair (46). 
Our observation of significantly lower appendicular LBM and no difference in total FM in 
SpA patients concur with the results of two previous studies (19, 22) , but oppose no  
difference in body composition reported elsewhere (23-26). Sari et al. (21) detected lower FM 
in male AS patients compared to healthy controls, although body composition was estimated 
by methods of lower accuracy (47). In the current study, one patient presented with extremely 
low adipose tissue values when compared to both reference data (48) and the other patients, 
thus potentially influencing between-group analyses of FM.  Comparison of body 
composition values between studies is challenging as most studies investigating SpA patients 
and healthy controls examine absolute values of FM and LBM (kg), bypassing body 
composition values relative to stature (kg/m2) despite group differences in height and/or mass 
(19, 23, 25). Furthermore, our study inclusion criteria did not impose any restrictions on 
exercise habits amongst the participants, whereas some of the studies cited admitted only 
sedentary participants or did not account for level of PA. In this study both patients and 
controls presented with appendicular LBM values that correspond to median reference data 
for white males of the same age group, but the observed FM % was lower than median 
reference values (48).  
We observed lower appendicular LBM in concert with a trend towards inferior muscle 
strength in the SpA patients. Direct comparison of muscle strength variables to other studies 
reporting analogous lower muscular force in AS patients (17-19) is challenging due to 
variation in measurement values, contraction type and muscle group studied. Previous studies 
have not matched patients and controls for level of PA (17-19), and the observed group 
difference may have been confounded by disparity in training status. In this study, patients 
were matched with a fellow control reporting corresponding levels of exercise as well as type 
of exercise. Nonetheless, we observed a significantly lower left knee extensor peak torque in 
the SpA patients, with a similar trend for the right leg. In contrast, a recent study (49) reported 
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no difference in isometric knee extensor strength between AS patients and healthy controls 
with similar levels of PA, as well as comparable levels of muscle force values when 
normalized to ultrasound-derived measures of QF anatomical CSA (specific strength). Along 
with total muscle volume, anatomical CSA is considered a strong predictor of muscle force 
(50). In the present study, the significantly larger total QF volume in control participants 
(Table 3) may be accounted for by the coincidental inferior femur length/body height ratio in 
patients (Table 1). Upon normalizing muscle force to QF maximal CSA (specific strength), 
the tending group difference in muscle force for the right leg was diminished (Table 3). Left 
leg muscle strength normalized to QF maximal CSA was however still significantly lower 
(p= 0.04) (Table 3) in patients, indicating a possible difference in muscle quality.  
In contrast to other reports (17, 18, 51), we observed similar levels of relative muscle 
endurance in patients and controls. The difference in total workload can be attributed to group 
diversity in muscle strength, and the number of repetitions at 30% MVC was similar between 
patients and controls (Table 3). Muscle endurance capacity is partially dependent on the 
expression of MHC isoforms (52), although a strong correlation to capillary density has also 
been suggested (53). We did not assess capillary density, but propose that comparable levels 
of muscle endurance portray the group similarity in muscle fiber composition.  
An important observation in the current study is the significantly smaller type 2 fibers in the 
patient population. Myofiber size is positively correlated to muscle strength (54, 55), and 
lower type 2 fiber CSA in SpA patients may explain the concomitant decreased muscle 
strength. Fiber hypertrophy is further reported to enhance maximal torque and rate of torque 
development (55, 56) and measures of MVC and RFD are considered to be highly related 
(57). The observation of no significant group difference in RFD despite lower maximum 
strength in the SpA patients was therefore surprising. However, our RFD data shows large 
variance, and combined with a small sample size, measures of RFD may have been inflicted 
by a type 2 error.  
Previous studies have detected abnormalities in muscle biopsies yielded from AS patients, 
with case series observations of angulated and atrophic muscle fibers (16, 27, 28). However, 
myofiber CSA values and adequate matching to healthy controls are lacking in these studies, 
rendering it impossible to compare fiber size and study population to our current research. 
Disease manifestations may also differ from what we encounter in our present-day clinical 
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practice due to modern therapeutic options. To our knowledge, ours is the first present-day 
study assessing muscle morphology in SpA. A contemporary publication (58) explored the 
effect of chronic inflammation on muscle characteristics by comparing biopsies from patients 
with rheumatoid arthritis (RA) and patients with osteoarthritis (OA). They observed no 
difference in ratio of type 2/type 1 fiber CSA, contrary to the significant difference identified 
in our cohort. Strength training can induce preferential hypertrophy of type 2 fibers, whereas 
endurance exercise has limited effect on fiber size (59-61). We attempted to eliminate the 
influence of strength training volume on type 2 fiber size by matching patients and controls on 
self-reported exercise habits. Increased fiber CSA is associated with an initial enhancement in 
the ratio of myonuclei to cell cytoplasm volume (62), consistent with the observed trend 
towards greater type 2 fiber myonucelar domain in our control participants (figure 3). 
Furthermore, the non-significant, but slightly higher number of myonuclei in biopsies from 
controls (table 4) demonstrate the strong dependency between fiber hypertrophy and addition 
of new myonuclei (54, 60). On an opposite note, recent studies have highlighted the 
possibility that muscle atrophy is not accompanied by loss of myonuclei (63, 64). Although 
highly speculative, the trend towards decreased myonuclear domain in type 2 fibers from SpA 
patients may illustrate the effect of catabolic pathways on previously enlarged muscle fibers.  
Satellite cells are important for skeletal muscle regeneration and for muscle hypertrophy in 
response to strength training (60). While enhanced number of satellite cells has been observed 
following strength training (54, 65, 66), pro-inflammatory pathways are associated with a 
decrease in volume and function of the satellite cell pool (12, 67). Interestingly, we observed 
a lower proportion of satellite cells in type 2 fibers in patients compared to controls. Although 
the group difference was non-significant (p= 0.13) (Table 4), we ponder on the possibility 
that inferior levels of satellite cells may curb the regenerative and/or adaptive ability of 
skeletal muscle in SpA patients. Noteworthy, no difference in satellite cell entity was 
observed between RA and OA patients (58), and no group difference was detected in in vitro 
satellite cell regenerative capacity (68), although this analysis was performed on a relatively 
small sub-sample. As emphasized by the authors, low-grade inflammation in the OA patients 
may have diluted the studied variables.  
The present study detected a wide range in numbers of ECM located macrophages, with a 
non-significant trend (p=0.11) towards higher amounts in the biopsies from SpA patients. 
Inflammatory processes in muscle tissue are commonly observed following altered use or 
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muscle injury, but may also be a consequence of autoimmune skeletal muscle disease (12, 
69). Neutrophils are usually the front-runners in the basic inflammatory response, followed by 
the invasion of different macrophage phenotypes. In the current study, level of neutrophils 
was comparable between patient and control participants. Due to the exploratory nature of the 
present study, biopsy samples were not stained for various macrophage phenotypes and we 
cannot estimate the proportion of pro- and anti-inflammatory macrophages. Pro-inflammatory 
macrophages secrete TNF and cytokines that may blunt myofiber regeneration, whereas anti-
inflammatory macrophages promote differentiation of myogenic precursor cells. Furthermore, 
animal models have linked high levels of insulin-like growth factor (IGF)-1, a hormone 
involved in hypertrophic pathways, with the anti-inflammatory macrophage phenotype (12, 
70).  Macrophages are scarce in untrained muscle in healthy subjects, and we advised study 
participants to refrain from exercise the last two days prior to biopsy sampling. However, 
since the volume of macrophages is reported to plateau several days post-exercise (70, 71), 
the 48- hour training ban may not have been sufficient to exclude exercise-driven release of 
macrophages. Nonetheless, the interesting trend towards higher level of ECM macrophages in 
the SpA patients may also be related to the disease in question.  
We did not measure level of TNF or interleukins associated with inflammatory, rheumatic 
pathways, and can only speculate as to whether the presence of underlying disease has had an 
impact on fiber type 2 protein turnover in the SpA patients. Increased level of pro-
inflammatory cytokines can curtail anabolic pathways (13) and inflate the activity of 
proteasomes (69, 72) with a prime catabolic effect on fast fibers (73). Conflicting results are 
reported regarding the influence of heat shock proteins (74-76) and reactive oxygen species 
(77-79) on muscle homeostasis in inflammatory rheumatic disease. Ancillary immunoblot 
analysis of muscle biopsies from this study can potentially identify whether the presence of 
SpA disease is associated with increased myogenic expression of factors known to curtail 
muscle hypertrophy or increase proteolysis .  
Patients included in this study reported low physical burden of disease. Likewise, both self-
assessed disease activity and serum inflammatory values indicate low current disease activity 
(80) compared to other studies with SpA patients (19, 21, 23, 24, 26, 81), although ESR and 
CRP presented with a wide range. However, patient self-report disclosed a history of disease 
flares in most patients. Although BMI was similar between groups, the control participants 
were significantly taller and heavier than the patients. A corresponding difference in height 
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has been observed in other SpA case-control studies (19, 20, 23, 26), often explained as 
increased kyphosis due to axial disease involvement. We did not observe such structural 
spinal changes in our patient group, and consider the difference in height a chance occurrence. 
The choice of a cross-sectional design imposes vulnerability to potential confounders. In the 
present study, no controls used pharmaceuticals on a regular basis. All patients reported 
continuous medication, with six patients taking NSAIDs and four patients on TNF-blockers 
(adalimumab, infliximab or certolizumab). Conducting a study on SpA patients with 
discontinued medication could perhaps unravel the true effect of disease on muscle tissue, but 
involves inescapable ethical barriers. Furthermore, mere inclusion of patients with an on-
demand need for medication would weaken the external validity, as the majority of patients 
require regular medication (82). NSAIDs are recommended as the first-line option for 
pharmaceutical treatment of axial SpA (7). This drug group acts by blocking cyclo-
oxygenase, an enzyme upstream to prostaglandin; a hormone-like mediator that may be 
involved in stimulating anabolic pathways. Conflicting results are reported in a systematic 
review (83) summarizing the effects of NSAIDs on parameters related to muscle growth. The 
majority of human trials do not uncover adverse effects of occasional use of NSAIDs on post-
exercise protein synthesis or muscle hypertrophy. Certain animal studies do however indicate 
the opposite (84, 85), and the consequence of longstanding use is unknown. Furthermore, 
evidence suggests NSAIDs may blunt satellite cell activity and thus potentially curtail the 
potential of muscle hypertrophy (13).  
Regarding TNF, prospective research has investigated the effect of initiating anti-TNF 
medication on parameters of body composition and the results are conflicting. Studies on SpA 
and psoriasis patients report shifts in body mass, FM and/or LBM after commencing anti-TNF 
medication (86-89). Discrepant results are reported in studies that noted no significant effect 
of TNF-blockers on body composition in patients with rheumatoid arthritis (90, 91). A novel 
study on patients with Crohns disease indicate a potential improvement in QF muscle mass 
and QF muscle strength subsequent to initiation of the TNF-blocker infliximab (92). The 
study lacked a control group, but observed no parallel change in self-reported diet or PA. 
Notwithstanding, increased nutritional uptake following infliximab may have confounded the 
results. There is a lack of human studies that histologically assess the impact of TNF-blockers 
on local muscle tissue. However, in mice with a genetic defect similar to dystrophy and 
myopathy, subcutaneous injections of TNF-blocker etanercept impeded inflammatory and 
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degenerative histological changes (93), and low-dose infliximab was beneficial for muscle 
strength and muscle fibrosis (94).  
In summary, the effect of pharmaceutics commonly used in SpA on muscle tissue is equivocal 
and we cannot discard a confounding effect on study variables. Sub-group analysis of 
medication in our patient cohort is conducted on a small sample and should be interpreted 
with caution. Compared to the NSAIDs group, patients on TNF-blockers presented with 
significantly lower ESR and CRP values (data not shown, see appendix). Additionally, we 
noted a moderate tendency towards lower BASDAI and BASFI in the TNF group, although 
low BASFI scores irrespective of medication suggest a floor effect (data not shown, see 
appendix). We further observed a trend for elevated maximal and specific strength in the 
NSAIDs subgroup, but no parallel divergence in muscle mass or myofiber size (data not 
shown, see appendix). Possibly related to medication, the difference in muscle strength may 
also reflect previous disease flares in the TNF subgroup that could have impeded their ability 
to engage in rigorous exercise. Collectively, our data may suggest a need for future SpA 
exercise studies to consider the potential effect of medication type on outcome variables.  
There are several limitations to our study. Despite aiming to pairwise match patients and 
controls for level of endurance- and strength exercise, an undisclosed group difference in 
training volume could have influenced study variables. Although one patients and his fellow 
control reported no leisure time exercise, our study may have been subject to selection bias by 
predominantly recruiting participants at the higher level of PA spectrum. In support, measures 
of maximal isometric muscle force in our study are comparable and slightly superior to values 
obtained using similar methods in a group of recreationally active young men and women 
(50). Furthermore, mean myofiber CSA corresponds to normative morphology data for 
Norwegian males, a report that also indicated a stronger relationship between fiber CSA and 
type and intensity of exercise rather than the amount of time spent on PA (95).  Notably, the 
present study admitted individual patients and controls presenting with a mean fiber size 
comparable to power-lifters (96).  
All tests and analyses were performed by researchers that were not blinded. Although 
attempts were made to standardize all measurements, knowledge of group membership may 
have influenced the outcome variables. The limited number of participants may entail low 
statistical power, possibly inflating the chance of making type 2 errors. Certain variables 
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presented with discrete effect sizes between right and left leg, perhaps related to the 
dispersion of collected data. Because of the exploratory nature of the study, we have 
discussed group differences in muscle morphology that did not adhere to the a priori alpha-
level of 0.05, and the observed trends need further investigation. Future studies with adequate 
statistical power are warranted to confirm our results and elucidate if catabolic pathways are 
up-regulated in SpA patients. 
In conclusion, the present exploratory study indicates that the presence of SpA disease is 
associated with reduced appendicular LBM, muscle strength and type 2 fiber CSA. Physical 
therapists can therefore be advised to include progressive resistance training in their treatment 
interventions for SpA patients as a possible countermeasure against the observed negative 
effects on muscle tissue.  
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Article Appendix 
Table 1.  Primary and secondary antibodies used during immunohistochemical staining. 
 Catalog number Manufacturer    Host Dilutions  
Primary antibodies     
Pax7   1 ea 13/14/13 DSHB Mouse 1:100 
SC71   1 11/8/12 DSHB Mouse 1:100 
CD68   M0718 Dako Mouse 1:300 
CD66b   CLB – B13.9 Saquin Mouse 1:500 
Laminin   Z0097 Dako Rabbit 1:400 
Dystrophin   Ab 15277 Abcam Rabbit 1:500 
Secondary antibodies      
Alexa flour 488 20010 Biotium Goat antimouse 1:200 
Alexa flour 594 20112 Biotium Goat antirabbit 1:200 
 
Supplementary statistical analyses: 
Table 2. Patient participants within-group paired sampled correlations of parameters of QF volume and 
CSA (Pat 01 excluded from analysis). 
Variable  QF total volume  
left leg, cm2 
QF max CSA 
left leg, cm2 
QF mean CSA 
left leg, cm2 
QF total volume 
right leg, cm2        
 
Pearson’s r 
P (2-tailed) 
N 
0.97 
<0.001 
9 
  
QF max CSA right 
leg, cm2 
Pearson’s r 
P (2-tailed) 
N 
 0.92 
0.001 
9 
 
QF mean CSA right 
leg, cm2 
Pearson’s r 
P (2-tailed) 
N 
  0.96 
<0.001 
9 
CSA: Cross-sectional area. QF: Mm. quadriceps femoris.  
Table 3. Control participants within-group paired sampled correlations of parameters of QF volume and 
CSA. 
Variable  QF total volume  
left leg, cm2 
QF max CSA 
left leg, cm2 
QF mean CSA 
left leg, cm2 
QF total volume 
right leg, cm2        
 
Pearson’s r 
P (2-tailed) 
N 
0.99 
<0.001 
10 
  
QF max CSA right 
leg, cm2 
Pearson’s r 
P (2-tailed) 
N 
 0.98 
<0.001 
10 
 
QF mean CSA right 
leg, cm2 
Pearson’s r 
P (2-tailed) 
N 
  0.99 
<0.001 
10 
CSA: Cross-sectional area. QF: Mm. quadriceps femoris.  
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Table 4. Patient participants within-group paired sampled correlations of parameters of QF function (Pat 
01 excluded from analysis). 
Variable  RFD left 
leg, Nm/10 
ms 
MVC left 
leg, Nm 
Number of 
repetitions, 
left leg 
Total 
workload 
(reps x 
kg) left 
leg, kg 
MVC 
Nm/QF 
total 
vol., 
left leg, 
Nm/cm3 
MVC 
Nm/QF 
max 
CSA, 
left leg, 
Nm/cm2 
RFD right leg, 
Nm/10ms 
Pearson’s r 
P (2-tailed) 
N 
0.45 
0.23 
9 
     
MVC right leg, 
Nm 
Pearson’s r 
P (2-tailed) 
N 
 0.89 
0.001 
9 
    
Number of 
repetitions, right 
leg 
Pearson’s r 
P (2-tailed) 
N 
  0.94 
<0.001 
9 
   
Total workload 
(reps x kg) right 
leg, kg  
Pearson’s r 
P (2-tailed) 
N 
   0.85 
0.04 
9 
  
MVC Nm/QF 
total vol., right 
leg, Nm/cm3 
Pearson’s r 
P (2-tailed) 
N 
    0.90 
0.001 
9 
 
MVC Nm/QF 
max CSA, right 
leg, Nm/cm2 
Pearson’s r 
P (2-tailed) 
N 
     0.87 
0.02 
9 
CSA: Cross-sectional area. MVC: Maximal voluntary contraction. Nm: Newtonmeter. QF: Mm. quadriceps 
femoris. RFD: Rate of force development. 
Table 5. Control participants within-group paired sampled correlations of parameters of QF function (Pat 
01 excluded from analysis). 
Variable  RFD left 
leg, Nm/10 
ms 
MVC left 
leg, Nm 
Number of 
repetitions, 
left leg 
Total 
workload 
(reps x 
kg) left 
leg, kg 
MVC 
Nm/QF 
total 
vol., 
left leg, 
Nm/cm3 
MVC 
Nm/QF 
max 
CSA, 
left leg, 
Nm/cm2 
RFD right leg, 
Nm/10ms 
Kendall’s τ 
P (2-tailed) 
N 
0.33 
0.18 
10 
     
MVC right leg, 
Nm 
Pearson’s r 
P (2-tailed) 
N 
 0.95 
<0.001 
10 
    
Number of 
repetitions, right 
leg 
Pearson’s r 
P (2-tailed) 
N 
  0.78 
0.007 
10 
   
Total workload 
(reps x kg) right 
leg, kg  
Pearson’s r 
P (2-tailed) 
N 
   0.84 
0.02 
10 
  
MVC Nm/QF 
total vol., right 
leg, Nm/cm3 
Pearson’s r 
P (2-tailed) 
N 
    0.83 
0.003 
10 
 
MVC Nm/QF 
max CSA, right 
leg, Nm/cm2 
Pearson’s r 
P (2-tailed) 
N 
     0.78 
0.07 
10 
CSA: Cross-sectional area. MVC: Maximal voluntary contraction. Nm: Newtonmeter. QF: Mm. quadriceps 
femoris. RFD: Rate of force development. 
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Table 6. Subject characteristics: NSAIDs vs TNF* 
Variable NSAIDs 
n= 6 
TNF 
n= 4 
P (95% CI lower; 
upper)^ 
Age (as of 31.12.14) 39 ±4.8 39 ±3.6 0.93 (-6.8;6.3) 
BMI, kg/m2 23.4 ±1.3 24.0 ±1.5 0.50 (-2.6;1.4) 
Diagnosis    
AS, n  4 2 - 
Axial SpA, n  2 1 - 
PsA, n 0 1 - 
HLA-B27 positive, n  5  4  - 
Time since diagnosis, years 9.5 ±10.5 10.8 ±2.2 0.82 (-13.8;11.3) 
Duration of symptoms, years 15.7 ±8.8 15.3 ±1.5 0.93 (-10.1;10.9) 
BASDAI score 3.1 ±0.4 2.2 ±1.6 0.15 (-0.51;0.09)£ 
BASFI score 1.3 ±0.8 0.4 ±0.5 0.11 (-0.2;1.9) 
BASMI score 2.2 ±1.4 2.6 ±0.7 0.61 (-2.2;1.4) 
CRP 11.7 ±6.4 0.0 ±0.0 0.007 (4.1;19.2) 
ESR 13.8 ±10.3 2.5 ±0.6 0.001 (1.0;2.6)£ 
Values are mean ±SD unless otherwise indicated. ^Comparison between patients on NSAIDs and TNF tested by 
independent samples t-test unless otherwise indicated. £: Log-transformed variable, independent samples t-test. 
AS: Ankylosing Spondylitis. BASDAI: Bath AS Disease Activity Index. BASFI: Bath AS Functional Index. 
BASMI: Bath AS Metrology Index BMI: Body mass index. CI: Confidence Interval. CRP: C-reactive protein. 
ESR: Erythrocyte sedimentation rate. NSAIDS: Non-steroidal anti-inflammatory drugs. TNF: Tumor Necrosis 
Factor. SpA: Spondyloarthritis. PsA: Psoriasis arthritis  
Table 7. Body composition analysis: NSAIDs vs TNF* 
Variable NSAIDs 
n=6 
TNF 
n= 4 
P (95% CI lower; 
upper)^ 
BMD, g/cm2 1.27 ±0.05 1.27 ±0.05 0.94 (-0.07;0.07) 
BMD, T-score 0.63 ±0.47 0.68 ±0.43 0.89 (-0.72;0.63) 
Lean mass, kg/m2 17.9 ±2.4 18.5 0.45 0.58 (-3.1;1.9)& 
Appendicular lean mass; RSMI, kg/m2 8.4 ±1.0 8.2 ±0.8 0.76 (-3.4;2.2) 
Body fat, % 20.8 ±9.1 23.6 ±1.9 0.49 (-12.3;6.7)& 
Android fat, % 23.7 ±13.6 27.6 ±5.8 0.60 (-20.8;12.9) 
Gynoid fat, % 20.2 ±8.7 22.2 ±3.4 0.67 (-12.8;8.7) 
*Values are mean ±SD unless otherwise indicated. ^Comparison between groups tested by independent samples 
t-test unless otherwise indicated. &: Equal variance not assumed. BMD: Bone mineral density. CI: Confidence 
Interval. RSMI: Relative skeletal muscle index. 
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Table 8. QF – parameters of volume, CSA and muscle function: NSADIs vs TNF*  
Variable NSAIDs 
n=6(#n=5) 
TNF 
n=4 
P (95% CI lower; 
upper)^ 
MVC right leg, Nm 217 ±29 175 ±28 0.053 (-0.6;84.4) 
MVC left leg, Nm# 193 ±39 154 ±39 0.18 (-23;101) 
QF total volume    
Right leg, cm2 2163 ±441 1987 ±203 0.48 (-375;727) 
Left leg, cm2# 2039 ±495 1899 ±345 0.65 (-553;832) 
QF mean CSA     
Right leg, cm2 64 ±11 59 ±4 0.44 (-9;19) 
Left leg, cm2# 60 ±12 57 ±8 0.65 (-14;21) 
QF max CSA    
Right leg, cm2 85 ±13 82 ±8 0.71 (-14;19) 
Left leg, cm2# 80 ±14 77 ±12 0.71 (-17;24) 
Specific strength     
MVC Nm/QF total vol., 
right leg, Nm/cm3 0.10 ±0.02 0.09 ±0.01 0.14 (-0.01;0.03) 
MVC Nm/QF total vol., 
left leg, Nm/cm3# 0.10 ±0.01 0.08 ±0.01 0.08 (-0.0;0.03) 
MVC Nm/QF max CSA, 
right leg, Nm/cm2 2.6 ±0.34 2.1 ±0.21 0.04 (0.01;0.90) 
MVC Nm/QF max CSA, 
left leg, Nm/cm2# 2.4 ±0.36 2.0 ±0.23 0.08 (-0.07;0.92) 
RFD    
Right leg, Nm/10 ms 1869 ±451 1486 ±376 0.20 (-249;1015) 
Left leg, Nm/10 ms# 1611 ±408 1632 ±204 0.93 (-553;512) 
Muscle endurance    
Number of repetitions, 
right leg 31 ±13 42 ±15 0.26 (-32;10) 
Number of repetitions, 
left leg# 35 ±11 46 ±15 0.28 (-31;10) 
Total workload 
(reps x kg), right leg, kg 537 ±224 586 ±206 0.73 (-373;275) 
Total workload 
(reps x kg), left leg, kg# 548 ±169 583 ±294 0.83 (-401;332) 
*Values are mean ±SD unless otherwise indicated. #: N= 5 patients, Pat 01 excluded due to prosthesis left hip. ^: 
Comparison between groups tested by independent samples t-test unless otherwise indicated. £: Log-transformed 
variable, independent samples t-test. CSA: Cross-sectional area. MVC: Maximal voluntary contraction. Nm: 
Newtonmeter. QF: Mm. quadriceps femoris. RFD: Rate of force development. 
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Table 9. Muscle morphology – parameters obtained from biopsy of m. vastus lateralis: NSAIDs vs TNF* 
Variable NSAIDs 
n=6 
TNF 
n=4 
P(95% CI lower; 
upper)^ 
Muscle fiber distribution    
Type 1, % 52 ±14 59 ±14 0.45 (-0.28;0.14) 
Muscle fibre CSA    
Type 1, µm2 5483 ±2443 4948 ±730 0.87 (-0.47;0.54)£ 
Type 2, µm2 5692 ±2241 5149 ±1248 0.67 (-2328;3414) 
Ratio CSA type 2/ type 1 1.06 ±0.19 1.03 ±0.17 0.81 (-0.24;0.30) 
Myonuclei     
Type 1, pr. fiber 3.7 ±1.3 3.5 ±1.0 0.83 (-1.6;1.9) 
Type 2, pr. fiber 4.3 ±1.2 3.7 ±1.0 0.46 (-1.1;2.3) 
Myonuclear domain    
Type 1, µm2 1475 ±253 1460 ±258 0.93 (-364;394) 
Type 2, µm2 1308 ±216 1415 ±299 0.53 (-480;266) 
Central nuclei    
Type 1, pr. fiber 0.03 ±0.03 0.01 ±0.01 0.17§ 
Type 2, pr. fiber 0.03 ±0.03 0.02 ±0.02 0.57 (-480;266) 
Satellite cells, Pax7-positive    
Type 1, pr. 100 fibres 6.6 ±3.9 11.9 ±11.9 0.38 (-1.71;0.72)£ 
Type 2, pr. 100 fibres 6.3 ±3.0 4.2 ±1.9 0.24 (-1.7;6.0) 
CD68 ECM, pr. 100 fibres 10.5 ±3.3 10.9 ±5.2 0.89 (-6.5;5.7) 
CD66b ECM, pr. 100 fibres 3.3 ±2.5 2.0 ±1.3 0.37 (-1.9;4.5) 
*Values are mean ±SD unless otherwise indicated. §: Mann-Whitney U test. CD68: marker for macrophages. 
CD66b: marker for neutrophils. CSA: Cross-sectional area. ECM: Extracellular matrix. £: Log-transformed 
variable, independent samples t-test. 
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Vi viser til søknad om forhåndsgodkjenning av ovennevnte forskningsprosjekt. Søknaden ble behandlet av 
Regional komité for medisinsk og helsefaglig forskningsetikk (REK sør-øst) i møtet 
12.06.2014. Vurderingen er gjort med hjemmel i helseforskningsloven (hfl.) § 10, jf. forskningsetikklovens § 4. 
Prosjektbeskrivelse 
Formålet med studien er å undersøke muskelstyrke og karakteristika ved muskelvev hos pasienter med 
spondyloartritt sammenlignet med friske kontroller. 
Spondyloartritt er en revmatisk inflammatorisk sykdom som rammer personer i ung alder. Tidligere studier har 
indikert at denne pasientgruppen har redusert muskelstyrke og utholdenhet sammenlignet med friske personer i 
samme alder. 
Det planlegges å inkludere 10 pasienter mellom 30 og 35 år med spondyloartritt fra Revmatologisk avdeling ved 
Diakonhjemmet Sykehus. I prosjektet skal det innhentes selvrapporterte data om medikamentbruk, 
sykdomsspesifikke bakgrunnsdata og sykdomsaktivitet samt fysisk funksjon. Det skal tas blodprøver og 
muskelbiopsi fra m. quadriceps femoris (rett lårmuskel). 
Muskelfunksjon skal måles isometrisk ved maksimal kraft og hastighet på kraftutmåling, samt ved en 
utholdenhetstest, disse undersøkelsene skal utføres under instruksjon av fysioterapeut. I tillegg skal muskelmasse 
måles ved Dual-energy X-ray absorptiometry (DXA) samt målinger av tverrsnittsareal og –volum av m. 
quadriceps femoris ved MR. 
Det primære endepunktet er størrelse av muskelfibre målt ved tverrsnittsareal på type I og II muskelfibre. 
Sekundære endepunkter er inflammasjon i muskelvev og forekomst av regulatorer av muskelfiberstørrelse målt 
ved hhv inflammatoriske celler og cytokiner, og proteiner som er involvert i muskelnedbryting. 
Region: Saksbehandler: Telefon: 
  Vår dato: Vår referanse: 
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Resultater skal sammenlignes med foreliggende referansemateriale ved Norges Idrettshøyskole fra friske 
personer. 
Biologisk materiale skal inngå i ny spesifikk forskningsbiobank, «Muskelvev hos pasienter med spondyloartritt», 
med ansvarshavende Truls Raastad ved Norsk Idrettshøyskole. 
 
Saksbehandling 
Prosjektet ble behandlet i møte 12.06.2014, og det ble fattet et utsettende vedtak. 
Komiteen ba om tilbakemelding på følgende merknader: 
Det forutsettes at biologisk materiale oppbevares i kun 5 år etter prosjektslutt, jf.helseforskningsloven § 38. Det 
bes om at formuleringen «…og du må ha høy grad av sykdomsaktivitet» i informasjonsskrivet revideres eller 
strykes. Det bes om en redegjørelse for hvilke friske personer som skal utgjøre kontrollgruppen samt hva disse 
har samtykket til. 
Søker har nå sendt tilbakemelding, denne ble mottatt 25.08.2014. 
Det fremkommer av tilbakemelding at oppbevaringstiden for biologisk materiale er endret til 5 år, mot tidligere 
15 år. Videre er informasjonsskrivet endret etter komiteens merknader. 
Det fremkommer også at kontrollgruppen skal rekrutteres blant friske voksne spesifikt til dette prosjektet. Det er 
utarbeidet et separat informasjonsskriv til disse. 
Ny vurdering 
Komiteens leder har vurdert tilbakemeldingen, og denne er å anse som tilfredsstillende i forhold til komiteens 
merknader. 
Vedtak 
Prosjektet godkjennes med hjemmel i helseforskningsloven §§ 9 og 33. 
Godkjenningen er gitt under forutsetning av at prosjektet gjennomføres slik det er beskrevet i søknaden og 
protokollen, og de bestemmelser som følger av helseforskningsloven med forskrifter. 
Godkjenningen gjelder til 01.06.2015. 
Komiteen godkjenner opprettelse av en spesifikk forskningsbiobank, "Muskelvev hos pasienter med 
spondyloartritt", med ansvarshavende Truls Raastad ved Norges Idrettshøyskole, med samme varighet som 
prosjektet. Biobankregisteret ved Nasjonalt Folkehelseinstitutt vil få kopi av dette brev. 
Av dokumentasjonshensyn skal opplysninger og innsamlet biologisk materiale oppbevares i 5 år etter 
prosjektslutt. Opplysninger og materiale skal oppbevares avidentifisert, dvs. atskilt i en nøkkel- og en datafil. 
Opplysningene skal deretter slettes eller anonymiseres, senest innen et halvt år fra denne dato. 
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Forskningsprosjektets data skal oppbevares forsvarlig, se personopplysningsforskriften kapittel 2, og 
Helsedirektoratets veileder for «Personvern og informasjonssikkerhet i forskningsprosjekter innenfor helseog 
omsorgssektoren».  
Prosjektet skal sende sluttmelding på eget skjema, jf. helseforskningsloven § 12, senest et halvt år etter 
prosjektslutt. 
Dersom det skal gjøres endringer i prosjektet i forhold til de opplysninger som er gitt i søknaden, må 
prosjektleder sende endringsmelding til REK, jf. helseforskningsloven § 11. 
Komiteens vedtak kan påklages til Den nasjonale forskningsetiske komité for medisin og helsefag, 
jf.helseforskningsloven § 10 tredje ledd og forvaltningsloven § 28. En eventuell klage sendes til REK sør-øst A. 
Klagefristen er tre uker fra mottak av dette brevet, jf. forvaltningsloven § 29. 
Med vennlig hilsen 
Knut Engedal 
Professor dr. med. 
Leder 
Anette Solli Karlsen 
Komitesekretær 
Kopi til:truls.raastad@nih.no; postmottak@diakonsyk.no; nina.hovland@fhi.no 
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Att. 2: Informed consent form (patients) 
 
 
Forespørsel om deltakelse i forskningsprosjektet 
 
 ”Har pasienter med spondyloartritt endringer i muskelvev og muskelfunksjon 
som følge av sin inflammatoriske revmatiske sykdom?” 
 
Dette er et spørsmål til deg om å delta i en forskningsstudie for å undersøke muskelvev og 
muskelfunksjon hos pasienter med spondyloartritt (SpA). Vi ber om din deltakelse i 
prosjektet, så fremt du oppfyller kriteriene: Du må ha en spondyloartritt diagnose som er 
bekreftet av en revmatolog, du må ha hatt symptomer i minst fem år. I tillegg må du være 
mann i alderen 30-45 år, du må ha en kroppsmasseindeks på mellom 18.5-30, og snakke norsk 
eller engelsk. Du kan ikke ha eller tidligere ha hatt artritt i hofter eller knær, 
muskelsykdommer og ellers ha hatt skader i ben eller føtter i løpet av de 12 siste mnd. Du kan 
heller ikke delta dersom du tar medikamenter som inneholder kortikosterioder eller dersom du 
er allergisk mot lokalbedøvelse (tilsvarende det man får hos tannlegen).  
 
Bakgrunn og hensikt 
Tidligere studier har vist at pasienter med spondyloartritt har redusert muskelmasse, 
muskelstyrke og utholdenhet sammenlignet med friske kontroller. I tillegg er det vist 
patologiske endringer i muskulaturen tett til virvelsøylen. Imidlertid er konsekvensene av 
sykdommen på den øvrige skjelett-muskulaturen ukjent, det er kun en 30 år gammel liten 
studie som har undersøkt dette. I tillegg er det uklart om redusert muskelstyrke og 
muskelkvalitet ved inflammatorisk sykdom hovedsakelig skyldes smerte, stivhet og redusert 
fysisk aktivitetsnivå eller om endringene kan tilskrives den inflammatoriske prosessen. Du får 
denne henvendelsen fordi du er pasient ved revmatologisk avdeling ved Diakonhjemmet 
Sykehus. 
Diakonhjemmet Sykehus og Norges Idrettshøgskole er ansvarlige for studien.    
 
Hva innebærer studien? 
Du skal møte på Norges Idrettshøgskole to ganger, og undersøkelsene vil vare i ca. 1 time. 
Tidspunkter avtales individuelt. De to siste dagene før forsøket må du avstå fra all krevende 
fysisk aktivitet (trening). I tillegg vil du måtte møte på et privat røntgeninstitutt for å ta MR 
bilde av lårmuskulaturen, også denne timen vil avtales individuelt.   
Undersøkelsen 
Du vil gjennomgå følgende tester og undersøkelser: 
Spørreskjema for å kartlegge relevant personlig bakgrunnsinformasjon og sykdomstilstand. 
Bevegelighetstest: det vil bli gjennomført en sykdomsspesifikk bevegelighetstest som 
innebærer målinger av bevegelighet i rygg, nakke og hofter.  
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DXA: det vil bli gjennomført en DXA-analyse for å måle kroppssammensetningen. Denne 
testen innebærer at du ligger stille fullt påkledd i ca. 10 min. 
Muskelfunksjonstest: testingen av muskelfunksjonen gjøres i et kneestrekkapparat som er låst 
ved 90◦ i kneleddet. 
Muskelbiopsi: det vil bli tatt en muskelbiopsi av lårmuskulaturen som vil gjennomføres på 
følgende måte: 
 Huden og bindevevet lokalbedøves der vevprøven skal taes. 
 Et snitt på ca. 1-2 cm gjøres gjennom hud og muskelfascien. 
 En nål med diameter på 6 mm føres inn (2-3 cm) og 1-3 små biter av muskulaturen tas 
ut (totalt 200 mg) 
 Snittet lukkes med tape (strips). 
Blodprøve 
 
Eventuelle ulemper ved å delta 
Deltakelse i prosjektet vil kreve en del tid og oppmerksomhet. Du må møte ved Norges 
Idrettshøgskole to ganger, og i tillegg vil du møte ved et privat røntgeninstitutt ved en 
anledning.  
Vevsprøvetakninger (muskelbiopsier) medfører en liten infeksjonsfare, og ubehag/smerter kan 
oppleves under inngrepet. Du kan også oppleve lette til moderate smerter 1-2 døgn etter 
inngrepet. Du vil få et lite arr etter snittet i huden; arret vil sakte bli mindre tydelig. Enkelte 
personer vil kunne få en fortykning av huden i arrområdet.  
 
Hva skjer med prøvene og informasjonen om deg?  
Prøvene tatt av deg og informasjonen som registreres om deg skal kun brukes slik som 
beskrevet i hensikten med studien. Alle opplysningene og prøvene vil bli behandlet uten navn 
og fødselsnummer eller andre direkte gjenkjennende opplysninger. En kode knytter deg til 
dine opplysninger og prøver gjennom en navneliste. Denne kodelisten vil fysisk være innelåst, 
slik at det kun er forskerne tilknyttet studien som har tilgang til den. Alle som får innsyn i 
informasjonen om deg har taushetsplikt. Innsamlede data vil bli anonymisert etter 5 år 
(kodelisten destrueres).  
Det vil ikke være mulig å identifisere deg i resultatene av studien når disse publiseres.  
Biobank 
Muskelbiopsiene vil bli oppbevart i en forskningsbiobank uten kommersielle interesser 
(vurdert av Regional Etisk komite). Hvis du sier ja til å delta i studien, gir du også samtykke 
til at det biologiske materialet og analyseresultater inngår i biobanken. Prøvene vil bli lagret 
til 2019. Ansvarlig for biobanken er professor Truls Raastad ved seksjon for fysisk 
prestasjonsevne ved Norges Idrettshøgskole. Det biologiske materialet kan bare brukes etter 
godkjenning fra Regional komité for medisinsk og helsefaglig forskningsetikk (REK). Hvis 
du sier ja til å delta i studien, gir du også ditt samtykke til at prøver og avidentifiserte 
opplysninger utleveres til Diakonhjemmet Sykehus.  
Frivillig deltakelse 
Det er frivillig å delta i studien. Du kan når som helst og uten å oppgi noen grunn trekke ditt 
samtykke til å delta i studien. Dette vil ikke få konsekvenser for din videre behandling. 
Dersom du ønsker å delta, undertegner du samtykkeerklæringen på siste side. Om du nå sier ja 
til å delta, kan du senere trekke tilbake ditt samtykke uten at det påvirker din øvrige 
behandling. Dersom du senere ønsker å trekke deg eller har spørsmål til studien, kan du 
kontakte Kristine Røren Nordén tlf: 920 43 801. 
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Innsynsrett og oppbevaring av materialet 
Hvis du sier ja til å delta i studien, har du rett til å få innsyn i hvilke opplysninger som er 
registrert om deg. Du har videre rett til å få korrigert eventuelle feil i de opplysningene vi har 
registrert. Dersom du trekker deg fra studien, kan du kreve å få slettet innsamlede prøver, 
opplysninger, med mindre opplysningene allerede er inngått i analyser eller brukt i 
vitenskapelige publikasjoner. 
 
Informasjon om utfallet av studien 
Etter at data er samlet inn og analysert vil alle forsøkspersonene få tilsendt et 
informasjonsbrev der vi presenterer resultatene fra studien.  
 
Forsikring 
Deltakerne i prosjektet er forsikret dersom det skulle oppstå skade eller komplikasjoner som 
følge av deltakelse i forskningsprosjektet. Norges Idrettshøgskole er en statlig institusjon og 
er således selvassurandør. Dette innebærer at det er Norges Idrettshøgskole som dekker en 
eventuell erstatning og ikke et forsikringsselskap. 
 
Finansiering 
Analysene av muskelbiopsiene vil bli finansiert av Revmatologisk avdeling ved 
Diakonhjemmet Sykehus.  
 
Publisering 
Resultatene fra studien vil offentliggjøres i internasjonale, fagfellevurderte tidsskrift. Du vil få 
tilsendt artiklene dersom du ønsker det.  
 
Samtykke 
Hvis du har lest informasjonsskrivet og ønsker å være med som forsøksperson i prosjektet, ber 
vi deg om å undertegne «samtykke om deltakelse» og returnere dette til en av personene som 
er nevnt nedenfor. Du bekrefter samtidig at du har fått kopi av og lest denne informasjonen.  
Det er frivillig å delta og du kan når som helst trekke deg fra prosjektet uten videre 
begrunnelse. Alle data vil, som nevnt ovenfor, bli avidentifisert før de blir lagt inn i en 
database og senere anonymisert.  
Dersom du ønsker flere opplysninger kan du ta kontakt med Kristine Røren Nordén på tlf. 920 
43 801 eller Silje Halvorsen Sveaas på tlf.  996 48 102. 
 
Med vennlig hilsen 
Kristine Røren Nordén (Mastergradsstudent i idrettsfysioterapi) 
Silje Halvorsen Sveaas (Stipendiat) 
Hanne Dagfinrud (Seniorforsker) 
Truls Raastad (Professor) 
 
Samtykkeerklæring følger på neste side.
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Samtykke til deltakelse i studien 
 
Jeg er villig til å delta i studien  
 
 
----------------------------------------------------------------------------------------------------------
------ 
(Signert av prosjektdeltaker, dato) 
 
 
Jeg bekrefter å ha gitt informasjon om studien 
 
 
----------------------------------------------------------------------------------------------------------
------ 
(Signert, rolle i studien, dato) 
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Att. 3: Informed consent form (controls) 
 
 
Forespørsel om deltakelse i 
forskningsprosjektet 
 
 ”Har pasienter med spondyloartritt endringer i muskelvev og 
muskelfunksjon som følge av sin inflammatoriske revmatiske sykdom?” 
 
Dette er et spørsmål til deg om å delta i en forskningsstudie for å undersøke muskelvev 
og muskelfunksjon hos pasienter med spondyloartritt (SpA). Vi ber om din deltakelse i 
prosjektet, så fremt du oppfyller kriteriene: Du må ha en spondyloartritt diagnose som 
er bekreftet av en revmatolog, du må ha hatt symptomer i minst fem år. I tillegg må du 
være mann i alderen 30-45 år, du må ha en kroppsmasseindeks på mellom 18.5-30, og 
snakke norsk eller engelsk. Du kan ikke ha eller tidligere ha hatt artritt i hofter eller 
knær, muskelsykdommer og ellers ha hatt skader i ben eller føtter i løpet av de 12 siste 
mnd. Du kan heller ikke delta dersom du tar medikamenter som inneholder 
kortikosterioder eller dersom du er allergisk mot lokalbedøvelse (tilsvarende det man får 
hos tannlegen).  
 
Bakgrunn og hensikt 
Tidligere studier har vist at pasienter med spondyloartritt har redusert muskelmasse, 
muskelstyrke og utholdenhet sammenlignet med friske kontroller. I tillegg er det vist 
patologiske endringer i muskulaturen tett til virvelsøylen. Imidlertid er konsekvensene 
av sykdommen på den øvrige skjelett-muskulaturen ukjent, det er kun en 30 år gammel 
liten studie som har undersøkt dette. I tillegg er det uklart om redusert muskelstyrke og 
muskelkvalitet ved inflammatorisk sykdom hovedsakelig skyldes smerte, stivhet og 
redusert fysisk aktivitetsnivå eller om endringene kan tilskrives den inflammatoriske 
prosessen. Du får denne henvendelsen fordi du er pasient ved revmatologisk avdeling 
ved Diakonhjemmet Sykehus. 
Diakonhjemmet Sykehus og Norges Idrettshøgskole er ansvarlige for studien.    
 
Hva innebærer studien? 
Du skal møte på Norges Idrettshøgskole to ganger, og undersøkelsene vil vare i ca. 1 
time. Tidspunkter avtales individuelt. De to siste dagene før forsøket må du avstå fra all 
krevende fysisk aktivitet (trening). I tillegg vil du måtte møte på et privat 
røntgeninstitutt for å ta MR bilde av lårmuskulaturen, også denne timen vil avtales 
individuelt.   
Undersøkelsen 
Du vil gjennomgå følgende tester og undersøkelser: 
Spørreskjema for å kartlegge relevant personlig bakgrunnsinformasjon og 
sykdomstilstand. 
Bevegelighetstest: det vil bli gjennomført en sykdomsspesifikk bevegelighetstest som 
innebærer målinger av bevegelighet i rygg, nakke og hofter.  
DXA: det vil bli gjennomført en DXA-analyse for å måle kroppssammensetningen. 
Denne testen innebærer at du ligger stille fullt påkledd i ca. 10 min. 
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Muskelfunksjonstest: testingen av muskelfunksjonen gjøres i et kneestrekkapparat som 
er låst ved 90◦ i kneleddet. 
Muskelbiopsi: det vil bli tatt en muskelbiopsi av lårmuskulaturen som vil gjennomføres 
på følgende måte: 
 Huden og bindevevet lokalbedøves der vevprøven skal taes. 
 Et snitt på ca. 1-2 cm gjøres gjennom hud og muskelfascien. 
 En nål med diameter på 6 mm føres inn (2-3 cm) og 1-3 små biter av 
muskulaturen tas ut (totalt 200 mg) 
 Snittet lukkes med tape (strips). 
 
Eventuelle ulemper ved å delta 
Deltakelse i prosjektet vil kreve en del tid og oppmerksomhet. Du må møte ved Norges 
Idrettshøgskole to ganger, og i tillegg vil du møte ved et privat røntgeninstitutt ved en 
anledning.  
Vevsprøvetakninger (muskelbiopsier) medfører en liten infeksjonsfare, og 
ubehag/smerter kan oppleves under inngrepet. Du kan også oppleve lette til moderate 
smerter 1-2 døgn etter inngrepet. Du vil få et lite arr etter snittet i huden; arret vil sakte 
bli mindre tydelig. Enkelte personer vil kunne få en fortykning av huden i arrområdet.  
 
Hva skjer med prøvene og informasjonen om deg?  
Prøvene tatt av deg og informasjonen som registreres om deg skal kun brukes slik som 
beskrevet i hensikten med studien. Alle opplysningene og prøvene vil bli behandlet uten 
navn og fødselsnummer eller andre direkte gjenkjennende opplysninger. En kode 
knytter deg til dine opplysninger og prøver gjennom en navneliste. Denne kodelisten vil 
fysisk være innelåst, slik at det kun er forskerne tilknyttet studien som har tilgang til 
den. Alle som får innsyn i informasjonen om deg har taushetsplikt. Innsamlede data vil 
bli anonymisert etter 5 år (kodelisten destrueres).  
Det vil ikke være mulig å identifisere deg i resultatene av studien når disse publiseres.  
Biobank 
Muskelbiopsiene vil bli oppbevart i en forskningsbiobank uten kommersielle interesser 
(vurdert av Regional Etisk komite). Hvis du sier ja til å delta i studien, gir du også 
samtykke til at det biologiske materialet og analyseresultater inngår i biobanken. 
Prøvene vil bli lagret til 2019. Ansvarlig for biobanken er professor Truls Raastad ved 
seksjon for fysisk prestasjonsevne ved Norges Idrettshøgskole. Det biologiske 
materialet kan bare brukes etter godkjenning fra Regional komité for medisinsk og 
helsefaglig forskningsetikk (REK). Hvis du sier ja til å delta i studien, gir du også ditt 
samtykke til at prøver og avidentifiserte opplysninger utleveres til Diakonhjemmet 
Sykehus.  
Frivillig deltakelse 
Det er frivillig å delta i studien. Du kan når som helst og uten å oppgi noen grunn trekke 
ditt samtykke til å delta i studien. Dette vil ikke få konsekvenser for din videre 
behandling. Dersom du ønsker å delta, undertegner du samtykkeerklæringen på siste 
side. Om du nå sier ja til å delta, kan du senere trekke tilbake ditt samtykke uten at det 
påvirker din øvrige behandling. Dersom du senere ønsker å trekke deg eller har 
spørsmål til studien, kan du kontakte Kristine Røren Nordén tlf: 920 43 801. 
 
Innsynsrett og oppbevaring av materialet 
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Hvis du sier ja til å delta i studien, har du rett til å få innsyn i hvilke opplysninger som 
er registrert om deg. Du har videre rett til å få korrigert eventuelle feil i de 
opplysningene vi har registrert. Dersom du trekker deg fra studien, kan du kreve å få 
slettet innsamlede prøver, opplysninger, med mindre opplysningene allerede er inngått i 
analyser eller brukt i vitenskapelige publikasjoner. 
 
Informasjon om utfallet av studien 
Etter at data er samlet inn og analysert vil alle forsøkspersonene få tilsendt et 
informasjonsbrev der vi presenterer resultatene fra studien.  
 
Forsikring 
Deltakerne i prosjektet er forsikret dersom det skulle oppstå skade eller komplikasjoner 
som følge av deltakelse i forskningsprosjektet. Norges Idrettshøgskole er en statlig 
institusjon og er således selvassurandør. Dette innebærer at det er Norges 
Idrettshøgskole som dekker en eventuell erstatning og ikke et forsikringsselskap. 
 
Finansiering 
Analysene av muskelbiopsiene vil bli finansiert av Revmatologisk avdeling ved 
Diakonhjemmet Sykehus.  
 
Publisering 
Resultatene fra studien vil offentliggjøres i internasjonale, fagfellevurderte tidsskrift. Du 
vil få tilsendt artiklene dersom du ønsker det.  
 
Samtykke 
Hvis du har lest informasjonsskrivet og ønsker å være med som forsøksperson i 
prosjektet, ber vi deg om å undertegne «samtykke om deltakelse» og returnere dette til 
en av personene som er nevnt nedenfor. Du bekrefter samtidig at du har fått kopi av og 
lest denne informasjonen.  
Det er frivillig å delta og du kan når som helst trekke deg fra prosjektet uten videre 
begrunnelse. Alle data vil, som nevnt ovenfor, bli avidentifisert før de blir lagt inn i en 
database og senere anonymisert.  
Dersom du ønsker flere opplysninger kan du ta kontakt med Kristine Røren Nordén på 
tlf. 920 43 801 eller Silje Halvorsen Sveaas på tlf.  996 48 102. 
 
Med vennlig hilsen 
Kristine Røren Nordén (Mastergradsstudent i idrettsfysioterapi) 
Silje Halvorsen Sveaas (Stipendiat) 
Hanne Dagfinrud (Seniorforsker) 
Truls Raastad (Professor) 
 
Samtykkeerklæring følger på neste side.
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Samtykke til deltakelse i studien 
 
Jeg er villig til å delta i studien  
 
 
---------------------------------------------------------------------------------------------------------- 
(Signert av prosjektdeltaker, dato) 
 
 
Jeg bekrefter å ha gitt informasjon om studien 
 
 
---------------------------------------------------------------------------------------------------------- 
(Signert, rolle i studien, dato) 
 
  
   
117 
Att. 4: Questionnaire including BASDAI and BASFI (patients) 
Muskelvev og muskelfunksjon ved spondyloartritt: 
Spørreskjema 
 
Konsekvenser av spondyloartritt på muskelvev og muskelfunksjon 
Vi ønsker å få din vurdering av egen helsetilstand. De første sidene inneholder spørsmål om 
personopplysninger, sykdomsaktivitet og fysisk funksjon. 
Alle svarene er viktige. Dette er en undersøkelse hvor vi ønsker å få vite hva DU mener om DIN 
EGEN helsesituasjon 
På forhånd takk for hjelpen! 
 
 
 Fyll ut dagens dato |__|__| |__|__| |__|__|__|__|  
                                      dag   måned   årstall  
|__|__|__|__|__|  
id. nr.  
|__|__|__|  
Initialer  
 
Høyde: 
Vekt: 
BMI: 
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Personopplysninger 
 Deltakernr  Dato - -  
GENERELLE SPØRSMÅL 
 
1a. Hva er din nåværende   Ugift / ikke samboende 
 sivilstand?  Ugift / samboende 
   Gift 
   Skilt 
   Enkemann / enke 
    
1b. Hvilken er din høyeste   Grunnskole 
 utdanning?  Allmenn videregående skole 
   Yrkesrettet videregående skole  
   Høyskole eller universitet, mindre enn 4 år 
   Høyskole eller universitet, mer enn 4 år 
    
    
2. Røyker du?  Nei, aldri røykt 
   Nei, har røykt tidligere; (mnd.-år) 
   Startet          -  
   Sluttet -  
   Ja, startet   -  
   Røyker i gjennomsnitt  sigaretter per dag   
3.  Hvilke medikamenter 
bruker du nå?  
  
 
 
4.  Har du noen sykdommer i 
tillegg til spondyloartritt?  
  
 
 
ARBEIDE 
 
4. Har du inntektsgivende arbeid nå?  Ja  Nei 
 Hvis nei, er du   Elev/student 
   Hjemmearbeidende 
   Arbeidsledig 
   Alderspensjonist 
   Uføretrygdet 
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 Vurdering av egen tilstand 
 
 
 Spørsmålene nedenfor gjelder hvordan du følte deg den siste uken. Marker ditt svar med å 
krysse i en rute ⊠. 
1. Hvordan vil du beskrive den generelle graden av utmattelse/tretthet du har erfart?   
 0 1 2 3 4 5 6 7 8 9 10  
Ingen            Svært høy 
2. Hvordan vil du beskrive den generelle graden av smerter i nakke-, rygg eller hofter i 
forbindelse med ryggplager? 
 0 1 2 3 4 5 6 7 8 9 10  
Ingen            Svært høy 
3. Hvordan vil du beskrive det generelle nivået av smerter/hevelse du har hatt i andre 
ledd enn nakken- ryggen eller hoftene?   
 0 1 2 3 4 5 6 7 8 9 10  
Ingen            Svært høy 
4. Hvordan vil du beskrive den generelle graden av ubehag du har hatt på eventuelle steder 
som gjør vondt ved berøring eller trykk?   
 0 1 2 3 4 5 6 7 8 9 10  
Ingen            Svært høy 
5. Hvordan vil du beskrive den generelle graden av stivhet du har opplevd om morgenen fra 
det tidspunktet du våkner?   
 0 1 2 3 4 5 6 7 8 9 10  
Ingen            Svært høy 
6. Hvor lenge varer morgenstivheten fra det tidspunktet du våkner?   
 0 1 2 3 4 5 6 7 8 9 10  
             
0 timer    1 time    2 timer eller mer 
7. Hvor aktiv var din sykdom i gjennomsnitt den siste uken? 
   
 
Ikke 
aktiv 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
8 
 
9 
 
10 
 
 
Meget 
aktiv 
 
 
 
  
   
120 
 
Vurdering av egen funksjon 
 
 
 Spørsmålene nedenfor gjelder hvordan du følte deg den siste uken. Marker ditt svar med å 
krysse i en rute ⊠. 
1. Ta på strømper eller strømpebukser uten assistanse eller ved bruk av hjelpemidler (for 
eksempel strømpepåtrekker) 
 0 1 2 3 4 5 6 7 8 9 10  
Lett            Umulig 
2. Bøye deg fremover fra midjen for å plukke opp en penn fra gulvet uten å bruke et 
hjelpemiddel 
 0 1 2 3 4 5 6 7 8 9 10  
Lett            Umulig 
3. Nå opp til en høythengende hylle uten bruk av hjelpemidler (f.eks. gripetang) 
 0 1 2 3 4 5 6 7 8 9 10  
Lett            Umulig 
4.  Reise deg fra en spisebordsstol uten armlener eller annen hjelp?   
 0 1 2 3 4 5 6 7 8 9 10  
Lett            Umulig 
5. Reise deg opp fra liggende stilling på gulvet uten hjelp  
 0 1 2 3 4 5 6 7 8 9 10  
Lett            Umulig 
6. Stå oppreist uten støtte i 10 min. uten å få ubehag 
 0 1 2 3 4 5 6 7 8 9 10  
Lett            Umulig 
7. Gå opp 12-15 trappetrinn uten å bruke rekkverk eller gåstøtte. En fot på hvert trinn  
 0 1 2 3 4 5 6 7 8 9 10  
Lett            Umulig 
8. Se deg over skulderen uten å vri kroppen 
 0 1 2 3 4 5 6 7 8 9 10  
Lett            Umulig 
9. Utføre fysisk krevende aktiviteter (f.eks. fysioterapiøvelser, hagearbeid eller sport)  
 0 1 2 3 4 5 6 7 8 9 10  
Lett            Umulig 
10. Utføre en hel dags aktiviteter enten hjemme eller på arbeid 
 0 1 2 3 4 5 6 7 8 9 10  
Lett            Umulig 
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Treningsvaner 
 
 
1a. I løpet av en vanlig uke;  Aldri eller meget sjelden 
 hvor ofte trener du   1-2 ganger per uke 
 kondisjon med en   3-5 ganger per uke 
 intensitet som gjør at du   Mer enn 5 ganger pr. uke  
 blir merkbart andpusten?   
    
1b. I løpet av en vanlig uke;   Aldri eller meget sjelden 
 hvor ofte trener du styrke  1-2 ganger per uke 
 med vekter, strikk, slynger  3-5 ganger per uke  
 eller egen kroppsvekt som  Mer enn 5 ganger pr. uke 
 motstand?   
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Att. 5: Questionnaire (controls) 
Muskelvev og muskelfunksjon ved spondyloartritt: 
Spørreskjema 
 
Konsekvenser av spondyloartritt på muskelvev og muskelfunksjon 
Vi ønsker å få din vurdering av egen helsetilstand. De første sidene inneholder spørsmål om 
personopplysninger, sykdomsaktivitet og fysisk funksjon. 
Alle svarene er viktige. Dette er en undersøkelse hvor vi ønsker å få vite hva DU mener om DIN 
EGEN helsesituasjon 
På forhånd takk for hjelpen! 
 
 
 
 Fyll ut dagens dato |__|__| |__|__| |__|__|__|__|  
                                      dag   måned   årstall  
|__|__|__|__|__|  
id. nr.  
|__|__|__|  
Initialer  
 
Høyde:  
Vekt: 
BMI: 
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Personopplysninger 
 Deltakernr  Dato - -  
GENERELLE SPØRSMÅL 
 
1a. Hva er din nåværende   Ugift / ikke samboende 
 sivilstand?  Ugift / samboende 
   Gift 
   Skilt 
   Enkemann / enke 
    
1b. Hvilken er din høyeste   Grunnskole 
 utdanning?  Allmenn videregående skole 
   Yrkesrettet videregående skole  
   Høyskole eller universitet, mindre enn 4 år 
   Høyskole eller universitet, mer enn 4 år 
    
    
2. Røyker du?  Nei, aldri røykt 
   Nei, har røykt tidligere; (mnd.-år) 
   Startet          -  
   Sluttet -  
   Ja, startet   -  
   Røyker i gjennomsnitt  sigaretter per dag   
3.  Hvilke medikamenter 
bruker du nå?  
  
 
 
 
ARBEIDE 
 
4. Har du inntektsgivende arbeid nå?  Ja  Nei 
 Hvis nei, er du   Elev/student 
   Hjemmearbeidende 
   Arbeidsledig 
   Alderspensjonist 
   Uføretrygdet 
Treningsvaner 
 
 
1a. I løpet av en vanlig uke;  Aldri eller meget sjelden 
 hvor ofte trener du   1-2 ganger per uke 
 kondisjon med en   3-5 ganger per uke 
 intensitet som gjør at du   Mer enn 5 ganger pr. uke  
 blir merkbart andpusten?   
    
1b. I løpet av en vanlig uke;   Aldri eller meget sjelden 
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 hvor ofte trener du styrke  1-2 ganger per uke 
 med vekter, strikk, slynger  3-5 ganger per uke  
 eller egen kroppsvekt som  Mer enn 5 ganger pr. uke  
 motstand?   
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Att. 6: Bath Ankylosing Spondylitis Metrology Index (BASMI) 
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Att. 7: Information on muscle biopsy wound care 
Informasjon til forsøkspersoner 
- Stell av sår etter muskelbiopsi 
 
Du er nå forsøksperson i prosjektet «Har pasienter med spondyloartritt endringer i muskelvev 
og muskelfunksjon som følge av sin inflammatoriske revmatiske sykdom?» der vi har tatt 
muskelprøver (biopsi) fra knestrekkerne (m. vastus lateralis). Dette er et lite inngrep som 
normalt ikke har noen negative følger, bortsett fra sår muskulatur noen dager. Imidlertid er det 
alltid en risiko for infeksjon ved slike inngrep. Vi ber deg derfor å følge rådene under. Om det 
skulle oppstå noe av medisinsk karakter som du tror kan settes i sammenheng med forsøket må 
du kontakte Truls. 
 
Det er nå viktig at du tar de forhåndsregler som skal til for at sårene dine skal gro godt. 
Følgende punkter er viktige: 
1. Hold såret tørt. Du bør ikke vaske området ved sårene eller dusje slik at tapen rundt 
sårene blir våte. Vann i dette området vil øke faren for infeksjon og det vil også føre til 
at tapen som skal holde sårflatene sammen løsner. Du kan dusje, men sørg for at du 
ikke får vann i nærheten av sårene (dusj forsiktig, bruk evt gladpack el ). 
2. Unngå trykk eller store drag i huden rundt såret. 
3. Om lag én uke etter at såret ble laget skal det ha dannet seg en skorpe som er så sterk at 
hudflatene holdes sammen og vann ikke trenger inn i såret. Først da kan du dusje på 
vanlig måte. Tilheling på 1 uke forutsetter selvfølgelig at punkt 1 er fulgt. 
 
Hvis ”stripsene” som holder såret sammen løsner før det har gått en uke bør du få på nye 
”stripps”. Ta da kontakt med én av kontaktpersonene under. 
Truls Raastad: 91368896 
 
 
